## HIRA, a conserved histone chaperone plays an essential role in low-dose stress response via transcriptional stimulation in fission yeast

## Moeko Chujo<sup>1</sup>, Yusuke Tarumoto<sup>1</sup>, Koichi Miyatake<sup>2</sup>, Eisuke Nishida<sup>2</sup>, and Fuyuki Ishikawa<sup>1</sup>

From the Departments of <sup>1</sup>Gene Mechanisms and <sup>2</sup>Cell and Developmental Biology, Graduate School of Biostudies, Kyoto University, Yoshida-Konoe-cho, Sakyo-ku, Kyoto 606-8501, Japan

\*Running title: Fission yeast HIRA in stress response

Address correspondence to: Fuyuki Ishikawa, MD, Kyoto University, Yoshida-Konoe-cho, Sakyo-ku, Kyoto 606-8501, Japan, Tel: +81 75 753 4195; Fax: +81 75 753 4197; E-mail: <u>fishikaw@lif.kyoto-u.ac.jp</u>

Keywords: Stress response; Cross tolerance; Histone chaperone; HIRA; Fission yeast

**Background:** HIRA is a conserved histone chaperone required for regulation of chromatin structure.

**Results:** Genes that encode HIRA proteins are responsible for cross tolerance. Specifically, stress-responsive gene expression was most profoundly compromised in HIRA disruptants.

**Conclusion:** HIRA is involved in cross tolerance via regulation of stress-responsive gene expression.

**Significance:** This study provides evidence that fission yeast HIRA functions in stress response.

## SUMMARY

Cells that have been pre-exposed to mild stress (priming stress) acquire transient resistance to subsequent severe stress even under different combinations of stresses. This phenomenon is called cross tolerance. Although it has been reported that cross tolerance occurs in many organisms, the molecular basis is not clear yet. Here, we identified  $slm9^+$  as a responsible gene for the cross tolerance in the fission yeast Schizosaccharomyces pombe. Slm9 is a homolog of mammalian HIRA histone chaperone. HIRA forms a conserved complex and gene disruption of other HIRA complex components, Hip1, Hip3 and Hip4, also yielded cross-tolerance-defective phenotype, a indicating that the fission yeast HIRA is involved in the cross tolerance as a complex. We also revealed that Slm9 was recruited to the stress-responsive gene loci upon stress treatment in an Atf1-dependent manner. The expression of stress-responsive genes under stress condition was compromised in HIRA

disruptants. Consistent with this, Pol II recruitment and nucleosome eviction at these gene loci were impaired in  $slm9\Delta$  cells. Furthermore, we found that the priming stress enhanced the expression of stress-responsive genes in wild-type cells that were exposed to the severe stress. These observations suggest that HIRA functions in stress response through transcriptional regulation.

Cells are equipped with stress response mechanisms at various levels in order to survive and proliferate under ever-changing environmental stresses. Cross tolerance is one of such stress response mechanisms. Cells that have been pre-exposed to mild stress (priming stress) are known to acquire transient resistance to subsequent severe stress. If the two stresses are of the same type, the phenomenon is called acquired tolerance. It is also known that this increased survival happens even under combinations of different types of stresses, such as heat stress and oxidative stress. This phenomenon is called cross tolerance. It has been reported that acquired tolerance and cross tolerance occur in a wide variety of species, including bacteria, plants, yeasts, and mammals (1-8).

Hormesis is a widely accepted term that more comprehensively describes cross tolerance (9,10). This phenomenon represents a biphasic dose response to toxins and stressors, with beneficial effects at low doses and harmful ones at high doses. Recent studies have provided new insights into hormesis as an application in anti-aging research (11,12). Thus, an understanding of the response to low-dose stress is important. However, generally, it is difficult to detect the response to low-dose stress because the low-dose stress does not induce a significant phenotype. Considering that the response to priming stress is important for survival under subsequent severe stress, the analysis of cross tolerance is expected to lead to further understanding of the response mechanism to low-dose stress.

In the fission yeast Schizosaccharomyces pombe, it is well known that a wide range of stresses lead to the activation of stress-activated mitogen-activated protein kinase (MAPK) Spc1/Sty1. The inactivation of this kinase causes hypersensitivities to various stresses (13-16). There are common stress-responsive genes, called core environmental stress response (CESR) genes whose expression is induced more than twofold under at least four of five types of stress conditions examined (17). CESR genes were regulated predominantly by Spc1 via the transcription factor Atf1. It has been proposed that the cross tolerance depends on nascent protein synthesis (7) and requires the induction of CESR genes (17). However, the molecular mechanism of the cross tolerance remains unclear.

Chromatin structure should be highly regulated in many cellular processes, such as DNA replication, repair or transcription. Accumulating evidence has shown that histone chaperones are one of the key proteins involved in those processes (18). Histone chaperones are known to associate with histones and facilitate the assembly and disassembly of nucleosomes. HIRA/HIR is one of the major histone chaperones that are conserved in many eukaryotic organisms (19). Whereas higher eukaryotes have a single HIRA protein (19-22), the fission yeast possesses two HIRA proteins (Slm9 and Hip1) (23,24), same as the budding yeast Saccharomyces cerevisiae (Hir1 and Hir2) (25). Fission yeast HIRA proteins stably associate with two other proteins, Hip3 and Hip4, and form a tetrameric complex (HIRA complex) (26,27). Recently, Cabin1 and UBN1 were identified as the human counterparts of Hip3 and Hip4. respectively (28-30), suggesting that the HIRA complex is evolutionarily conserved. HIRA is the histone chaperone for histone H3-H4 and is replication-independent involved in the nucleosome deposition pathway, whereas another histone chaperone CAF-1 is coupled to DNA replication (31-34).

HIRA has been shown to function in transcription as well. HIRA proteins were first

identified in the budding yeast as a negative regulator of histone gene expression (25,35). It has been reported that the budding yeast HIR complex interacts with nucleosomes and prevents the remodeling activity of the SWI/SNF complex (36). The ectopic expression of HIRA in human cells also represses the transcription of histones (37). In the fission yeast, HIRA is required for the suppression of Tf2 long terminal repeat (LTR) retrotransposons, normally repressed genes, or cryptic antisense transcripts (38). Consistent with its repressive role in transcription, HIRA also functions in heterochromatin assembly and silencing. In human cells, the formation of senescence-associated heterochromatin foci depends on HIRA (39). Loss of the fission yeast HIRA complex components results in silencing defects at the centromere and mating type loci (27). Recent study has also demonstrated that a complex formed by the histone chaperone Asf1 and HIRA spreads across silenced regions via its association with the chromodomain protein Swi6 to facilitate deacetylation heterochromatin histone and spreading in the fission yeast (40). On the other hand, HIRA can also act as a positive regulator of transcription. The N-terminal and C-terminal halves of chicken HIRA regulate different sets of cell-cycle-related genes positively and negatively, respectively (41). Mutations in the budding yeast HIR genes display strong synthetic defects or lethality when combined with mutations in the genes encoding the transcription elongation factor FACT components (42). In higher eukaryotes, HIRA is involved in the incorporation of H3.3 variant histones into transcriptionally active genes (33,43,44). However, it is not clear whether HIRA is involved in transcriptional activation in the fission yeast.

In this study, we found that the fission yeast  $slm9^+$  is responsible for the cross tolerance. The disruption of each component gene of the HIRA complex led to defects in the cross tolerance. In wild-type cells, Slm9 was located at several stress-responsive gene loci under the stress condition and this localization is dependent on Atf1. disruption caused impaired HIRA stress-responsive expression, gene stress-dependent Pol II recruitment. and nucleosome eviction. Moreover, it was suggested that the priming stress facilitates stress-responsive gene expression in wild-type cells under the severe stress. Together, these results highlight the novel function of the fission yeast HIRA in stress

response.

## **EXPERIMENTAL PROCEDURES**

Yeast strains and general techniques- S. pombe strains used in this study are listed in Table 1. Growth media and basic techniques for the fission yeast have been described previously (45,46). Cells were grown in the rich medium YES or the synthetic medium SD and supplemented with amino acids as required.

Stress experiments- For the cross tolerance and acquired tolerance experiments, cells were grown in duplicate to the logarithmic phase in YES medium at 32°C. Two cultures each were subjected and not subjected to the priming stress, respectively, for 1 h and centrifuged gently (780 g for 1 min) to remove the medium. Subsequently, both cultures were resuspended in YES medium and severe stress was applied for 1 h. The stress conditions are described below. (P) and (S) indicate priming stress and severe stress, respectively. Oxidative stress: H<sub>2</sub>O<sub>2</sub> was added to make a final concentration of 0.1 mM (P) or 25 mM (S). Heat stress: Cells were cultured in a 40°C (P) or 46°C (S) water bath. Osmotic stress: YES medium containing 2.4 M KCl was added to make a final concentration of 0.6 M (P) or 2.4 M (S). After the above stress treatment, the cells were immediately collected by gentle centrifugation (400 g for 2 min) and diluted with YES medium. Five hundred cells per plate were plated onto YES plates and the number of colonies was counted after incubation for 4 days at 32°C. Viability was calculated as percentage of the number of colonies for 500 cells.

For the colony-spotting assay, the cells were grown to the logarithmic phase in YES medium at  $32^{\circ}$ C. Then, the cells were serially diluted from 5  $\times 10^{6}$  to  $5 \times 10^{3}$  cells/ml (tenfold dilution) and 5 µl of each was spotted onto YES plates. Incubation was carried out for 3-4 days at 32°C. For heat stress, cells that were spotted onto YES plates were incubated for 3-4 days at 37°C, or for 1 h at 47°C followed by incubation for 3-4 days at 32°C. For the other stresses, YES plates containing the following compounds were used: 2 mM H<sub>2</sub>O<sub>2</sub>, 50 µM menadione, 1.2 M KCl, 2 M sorbitol, and 0.1 M CaCl<sub>2</sub>.

*Chromatin immunoprecipitation*– The cells were grown in duplicate to the logarithmic phase in YES medium at  $32^{\circ}$ C. One aliquot was used as the unstressed control and the other aliquot was exposed to  $40^{\circ}$ C for 15 min. Subsequently, the

cells  $(2.5 \sim 4 \times 10^8 \text{ cells})$  were cross-linked by adding 1% formaldehyde for 30 min at 25°C and the cross-linking was stopped by treating with 125 mM glycine on ice for 5 min. The cell pellets were washed twice with ice-cold water and twice with lysis buffer 1 (50 mM HEPES-KOH [pH 7.5], 140 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate). The cell pellets were resuspended in lysis buffer 1 containing 50 mM NaF, 0.1 mM Na<sub>3</sub>VO<sub>4</sub>, 1 mM PMSF, and  $1 \times$ Complete (Roche), and broken with zirconia beads using a Multi-Beads Shocker (Yasui Kikai) at 4°C. The lysates were sonicated with Sonifier 250 (Branson) to yield chromatin fragments having an average size of 500 bp. The sonicated lysates were spun at 17,800 g for 15 min at 4°C. The supernatant was immunoprecipitated with mouse anti-Myc antibody (sc-40 Santa Cruz) or mouse anti-RNA polymerase II CTD antibody (05-623 Millipore) for 2 h at 4°C, and this was followed by the addition of magnetic beads (Dynal). After incubation for 1.5 h at 4°C, the beads were washed once with lysis buffer 1 containing 50 mM NaF, 0.1 mM Na<sub>3</sub>VO<sub>4</sub>, 1 mM PMSF, and  $1 \times$  Complete (Roche); once with lysis buffer 1 containing 500 mM NaCl and 1 mM PMSF; once with lysis buffer 2 (10 mM Tris-HCl [pH 8.0], 1 mM EDTA, 0.25 M LiCl, 0.5% NP-40, 0.5% sodium deoxycholate); and twice with TE (10 mM Tris-HCl [pH 8.0], 1 mM EDTA). The beads were resuspended in TER (TE containing 10 µg/ml RNase) and incubated for 15 min at 37°C. The samples were adjusted to 0.25% SDS and 250 µg/ml proteinase K, and incubated at 37°C overnight. This was followed by another incubation for 6 h at 65°C. The eluted subjected to phenol/chloroform DNA was extraction and precipitated with ethanol. The purified DNA was analyzed by real-time PCR using the StepOnePlus<sup>TM</sup> Real-Time PCR System and Power SYBR Green PCR master mix (Applied Biosystems). The nucleotide sequences of the primer sets are listed in Table S1.

*RT-PCR*– Total RNA was isolated as previously described (47) and treated with 0.625 U/g RNA of RNase-free DNase I (TaKaRa) to digest genomic DNA. cDNA samples were synthesized using AMV Reverse Transcriptase (Life Sciences Advanced Technologies, Inc.) and Random Primer (nonadeoxyribonucleotide mixture). The primer sequences are available on request. Real-time PCR was performed using the StepOnePlus<sup>TM</sup> Real-Time PCR System and Power SYBR Green PCR master mix (Applied Biosystems). The nucleotide sequences of the primer sets for real-time PCR are listed in Table S1.

Microarray analysis- The cells were grown in quadruplicate at 32°C to the logarithmic phase and an aliquot was collected as the unstressed control. The other three aliquots were exposed to  $40^{\circ}$ C for 1 h, 25 mM H<sub>2</sub>O<sub>2</sub> for 1 h, or  $40^{\circ}$ C for 1 h followed by 25 mM H<sub>2</sub>O<sub>2</sub> for 1 h, respectively. Total RNA was purified as described for RT-PCR. All the 12 RNA samples were analyzed with GeneChip Yeast Genome 2.0 Array (Affymetrix) according to the manufacturer's instructions. After using the RMA algorithm to obtain the summarized probeset-level expression data, the array data were transferred to GeneSpring 7.3 Technologies) microarray analysis (Agilent software for gene ontology (GO) analysis. Standard hypergeometric distribution was used to calculate the p-values for individual GO terms. Significant enrichment of GO was selected using a p-value of <0.05. To avoid the detection of false positives, the Benjamini-Yekutieli correction method was applied to obtain the corrected p-values. The microarray data are available at Gene Expression Omnibus (GEO) under accession number GSE35281.

Preparation of mononucleosomal DNA- The cells were grown in duplicate to the early logarithmic phase in YES medium at 32°C. One aliquot was used as the unstressed control and the other aliquot was exposed to 40°C for 15 min. Subsequently, mononucleosomal DNA was obtained as described previously (48) with some modifications. Cell wall was digested with 1 mg/ml Zymolyase 100T (Seikagaku Corporation) for 40 min at 35°C. Micrococcal nuclease (MNase) digestion was performed with MNase to final concentration of 133 U/ml. а Mononucleosomal DNA fragments were purified from the agarose gel using QIAquick Gel Extraction Kit (Qiagen).

Nucleosome-scanning analysis-The nucleosome-scanning analysis was performed as described previously (49,50). Genomic DNA was obtained from the same protocol as for the preparation of mononucleosomal DNA, without the crosslinking, MNase treatment and gel purification step. Five nanograms of purified mononucleosomal and genomic DNA were analyzed by real-time PCR using the StepOnePlus<sup>TM</sup> Real-Time PCR System and Power SYBR Green PCR master mix (Applied Biosystems). Ten overlapping primer pairs were set downstream of nucleosome depleted region (NDR) (50,51). The nucleotide sequences of the primer sets were designed by reference to the previous report (50) as listed in Table S1.

## RESULTS

*Cross tolerance in fission yeast*– We first confirmed cross tolerance in the fission yeast. Wild-type (JK317) cells were treated or not treated with mild (priming) stress and subsequently subjected to severe stress, using combinations of heat, oxidative, and osmotic stresses, and cell viability was compared (Fig. 1). In contrast to the case of the budding yeast (7), the combination of mild oxidative stress and severe heat stress induced cross tolerance. Other combinations examined also induced cross tolerance. Overall, we conclude that in the fission yeast, various combinations of stresses generally induce cross tolerance.

Identification of responsible gene of cross-tolerance-defective mutant- In order to identify the factor involved in cross tolerance, we performed genetic a screen for cross-tolerance-defective mutants and isolated several mutants (Tarumoto, Y., Kanoh, J. and Ishikawa, F., submitted for publication). Among them, 7-4 mutant, which showed clearly the cross-tolerance-defective phenotype, was chosen for further analysis (Fig. S1A). 7-4 mutant was backcrossed three times with the parental wild-type strain. Tetrad analysis revealed that the cross-tolerance-defective phenotype of 7-4 mutant was caused by a single mutation. In addition to the cross-tolerance-defective phenotype, we found that 7-4 mutant showed strong sensitivity to heat shock (37°C) and 0.1 M CaCl<sub>2</sub> treatment (Fig. S1B). The responsible gene of 7-4 mutant was cloned by complementation of heat and CaCl<sub>2</sub> sensitivities with S. pombe genomic library (pTN-L1) and subsequent sequencing revealed its identity as  $slm9^+$ . We verified that a single nucleotide deletion occurred at nucleotide 1451 in the ORF of  $slm9^+$  in 7-4 mutant (Fig. S1C). Slm9 is the homolog of mammalian HIRA in the fission yeast. HIRA is a histone chaperone that is replication-independent involved in the pathway nucleosome deposition and transcriptional control.

HIRA complex is involved in cross tolerance– The fission yeast has two HIRA/HIR proteins, Slm9 and Hip1 (23,24). In order to verify the function of the fission yeast HIRA in cross tolerance, we constructed  $slm9\Delta$  and  $hip1\Delta$  strains and examined the cross tolerance phenotype. Both showed  $slm9\Lambda$ and  $hip1\Delta$ cells the cross-tolerance-defective phenotype under the combination of mild heat stress and severe oxidative stress (Fig. 2A). As Slm9 and Hip1 form a complex with two other proteins, Hip3 and Hip4 (26,27), we also examined these HIRA complex subunit disruptants. We found that both  $hip3\Delta$  and  $hip4\Delta$  cells showed the cross-tolerance-defective phenotype, similar to  $slm9\Delta$  and  $hip1\Delta$  cells (Fig. 2B). These results suggest that the fission yeast HIRA functions as a complex to confer cross tolerance.

To examine the possibility that HIRA disruptants are specifically sensitive to the combination of mild heat stress and severe oxidative stress, the cells were treated with other stress combinations.  $slm9\Delta$  and  $hip1\Delta$  cells also showed the cross-tolerance-defective phenotype when treated with combinations of mild oxidative stress and severe heat stress, and mild osmotic stress and severe oxidative stress (Fig. 2C). These experiments demonstrated that the fission yeast HIRA is involved in cross tolerance regardless of the stress combination. Moreover, the cells were also treated with combinations of same types of stresses, namely, mild oxidative stress and severe oxidative stress (acquired-tolerance-inducible stress). Acquired tolerance was defective in  $slm9\Delta$ and  $hip1\Delta$  cells as well as cross tolerance (Fig. 2D). Hereafter, we used the combinations of mild heat stress and severe oxidative stress as the cross-tolerance-inducible stress.

To determine whether the function of HIRA in stress response is a general feature of histone chaperones, we analyzed other histone chaperone mutants,  $pcf1\Delta$  and  $nap1\Delta$ . Pcf1 is a large subunit of histone chaperone CAF-1 that loads histone H3-H4 onto DNA and is involved in the replication-dependent nucleosome deposition pathway (34,52). Nap1 is involved in the transfer of histone H2A-H2B from the cytoplasm to the nucleus and the deposition of histones onto DNA (53). Cross tolerance occurred in both  $pcf1\Delta$  and  $nap1\Delta$  cells, similar to the case of wild-type cells (Fig. 2E). These results raise an interesting possibility that among histone chaperones, HIRA is specifically involved in cross tolerance.

HIRA functions particularly under low-dose stress- As we examined the cross tolerance phenotype under various combinations of heat, oxidative, and osmotic stresses, we next investigated the viability of cells lacking each subunit of the HIRA complex under the single stress condition (Fig. 3). The HIRA subunit disruptants (*slm*9 $\Delta$ , *hip*1 $\Delta$ , *hip*3 $\Delta$ , and *hip*4 $\Delta$ ) were not so sensitive to osmotic stress (2 M sorbitol and 1.2 M KCl) and oxidative stress caused by 2 mM  $H_2O_2$ , whereas spc1 $\Delta$  mutant, which is known to be sensitive to a wide variety of stresses, showed strong sensitivity. On the other hand, the HIRA subunit disruptants showed severe sensitivity to heat shock (37°C, 3 days) and oxidative stress caused by 50 µM menadione. Although the HIRA subunit disruptants showed varied sensitivities to distinct forms of stress. the cross (acquired)-tolerance-defective phenotype of  $slm9\Delta$ and  $hip1\Delta$  cells was observed under different stress combinations (Fig. 2A, C and D). These results further suggest the stress-type-independent function of HIRA in the cross tolerance. It is known that menadione generate intracellular reactive oxygen species and exert weak oxidative stress on the cells (54). It should be noted that the HIRA subunit disruptants showed higher sensitivity to menadione than H<sub>2</sub>O<sub>2</sub>. Moreover, they were more sensitive to weak and chronic heat shock (37°C, 3 days) than strong and acute heat shock (47°C, 1 h). These observations suggest that HIRA responds to low-dose stress specifically, consistent with its response to the priming stress in the cross tolerance.

HIRA is localized at stress-responsive gene loci upon stress treatment- As the fission yeast HIRA has a function in the cross tolerance, we examined the protein levels of Slm9 and Hip1 under the stress condition. Considering the protein levels of loading control (Cdc2), it appeared that Hip1 was more abundant than Slm9. The protein levels of both Slm9 and Hip1 did not change significantly during the course of the priming stress treatment (Fig. 4A). We also examined Slm9 localization using a strain whose chromosomal copy of  $slm9^+$  was tagged with the GFP sequence. In cells expressing Slm9-GFP, fluorescent signals were observed in the nuclei, as reported previously (23). This nuclear localization was not altered significantly under the stress condition (Fig. S2A). In addition, the chromatin fractionation assay was performed to determine HIRA localization biochemically (Fig. S2B). Slm9 both enriched in and Hip1 were the chromatin-bound fractions, and the distributions of Slm9 and Hip1 among different fractions did not change notably under the stress condition (Fig. S2C).

To further investigate whether HIRA is localized at specific chromatic loci upon stress treatment, the chromatin immunoprecipitation (ChIP) assay was performed. Slm9 was enriched at both the promoters and ORFs of CESR genes  $(ctt1^+, gpx1^+, and hsp9^+)$  in a stress-dependent manner. However, such physical association of Slm9 was not observed at non-stress responsive loci ( $poll^+$  ORF and dh) (Fig. 4B). Thus, whereas the protein levels and the chromatin association of HIRA, revealed by Western blotting and chromatin fractionation assay, did not show distinct alteration. HIRA localization at chromatin revealed by the ChIP assay changes under the stress condition.

CESR genes were primarily regulated by Spc1 through its downstream b-ZIP transcription factor Atf1 (17). We hypothesized that specific localization of Slm9 at CESR gene loci is determined by Atf1. Indeed, Slm9 recruitment to CESR gene loci is almost totally dependent on Atf1 (Fig. 4B). This result suggests that Atf1 determines the stress-dependent HIRA recruitment to chromatin.

HIRA is required for stress-responsive gene transcription- Histone chaperones have been surmised to play important roles in transcriptional regulation (18). As the fission yeast HIRA was localized at the stress-responsive gene loci upon stress treatment, we hypothesized that the fission yeast HIRA complex may play a role in the stress response through the transcriptional control of stress-responsive genes. RT-PCR was performed to examine the expression of several CESR genes under the stress conditions in wild-type,  $slm9\Delta$ , and  $hip1\Delta$  cells. slm9 and hip1 disruption decreased the expression of many CESR genes  $(ctt1^+, gpx1^+, gpd1^+, and tps1^+)$  under the priming stress compared to wild-type cells (Fig. 5A). There were some exceptions, such as  $hsp9^+$  and  $hsp16^+$ that showed increased basal expression in the mutants (Fig. 5A). This basal up-regulation of some CESR genes is consistent with previous reports (26,38). In general, all the genes examined showed smaller differences in transcriptional levels between the non-stress condition and the priming stress condition in the mutant cells compared to the wild-type cells. In contrast, slm9 and hip1 disruption increased the expression of those genes under the severe stress condition (Fig. S3). Taken together, the results suggest that HIRA is required for the proper expression of stress-responsive genes. In addition to the gene expression, ChIP assay was carried out to examine the transcriptional kinetics at several gene loci in the wild-type and  $slm9\Delta$  cells under the stress condition. As expected, RNA polymerase II (Pol II) was recruited to both promoters and ORFs of CESR genes  $(ctt1^+, gpx1^+, and hsp9^+)$  in the wild-type cells subjected to stress treatment, whereas this recruitment was impaired in  $slm9\Delta$ cells. On the other hand, basal stress-independent Pol II recruitment to non-stress responsive loci  $(poll^+ \text{ ORF and } dh)$  was unaffected in *slm9* $\Delta$  cells (Fig. 5B). This result is consistent with the expression of CESR genes (Fig. 5A). Therefore, our results indicate that HIRA plays an important role in Pol II recruitment and progression, and the transcriptional activation of stress-responsive genes under the low-dose stress conditions.

HIRA particularly regulates stress-responsive genes under stress conditions- To determine whether HIRA specifically regulates stress-responsive genes or not, microarray analysis was carried out on wild-type,  $slm9\Delta$ , and  $hip1\Delta$ cells under four conditions: control, priming stress alone, priming stress followed by severe stress, and severe stress alone. Signal concordance between two arrays was evaluated using Pearson's correlation coefficient  $(r^2)$ . A strong correlation  $(r^2>0.998)$  was noted between slm9 $\Delta$  and hip1 $\Delta$ samples under all conditions (Fig. S4), consistent with the previously reported strong correlation of gene expression between  $slm9\Delta$  and  $hip1\Delta$  cells under the normal condition (38).

We identified genes that exhibited twofold or greater change in the stress-treated samples compared to the control, and categorized them by GO classification. The GO terms that were enriched in induced and repressed genes under all conditions are listed in Table S2 and Table S3, respectively. Among these results, we focused on the priming stress condition because the response to the priming stress would be important for survival under the subsequent severe stress. The principal GO terms that are most significantly associated with the priming-stress-induced genes are selected from Table S2 and shown in Table 2. GO analysis identified "cellular response to stress," "meiosis," and "M phase" as the major enriched biological functions in both wild-type cells and mutants. Whereas the p-values of "meiosis" and "M phase" were similar between the wild-type cells and the mutants, the number of genes

enriched into "cellular response to stress" was much larger in the wild-type cells than in the mutants. In addition, GO terms, including "cellular response to oxidative stress" and "oxidoreductase activity," were only found in the wild-type cells. These results are consistent with the reduced CESR gene expression in the mutants under the priming stress condition (Fig. 5A). On the contrary, the number of genes enriched into "cellular response to stress" was much larger in the mutant cells than in the wild-type cells under the severe stress condition, which was again consistent with the results of RT-PCR (Fig. S3 and Table S2) (See Discussion).

further confirm the То difference in expression between the wild-type cells and the mutants under the priming stress condition, the fold change of gene expression was plotted under the priming stress condition compared to the control condition. The fold change in expression of all genes was smaller in the mutants than in the wild-type cells (Fig. 6A). Similarly, the fold change in expression of CESR genes and genes whose expression was increased more than twofold in the wild-type cells decreased significantly in the mutants (Fig. 6B and C). Moreover, among the priming-stress-induced genes of the wild-type cells, we selected genes that showed twofold or higher change in the wild-type cells compared to each mutant, and performed GO analysis of those genes. GO analysis identified "cellular response to stress" as the most significant term (Table 3). Thus, although HIRA may be required for global gene expression, it is particularly plays an important role in regulating the stress-responsive genes.

regulates stress-responsive HIRA gene expression via nucleosome eviction- To explore the mechanism by which HIRA regulates stress-responsive transcription, gene the nucleosome-scanning analysis of  $ctt1^+$  region was performed. In wild-type cells, the position of +1 to +3 (relative to the transcription start site (TSS)) nucleosomes, as reflected by MNase sensitivity, were detected as peaks and these peaks were diminished upon heat stress (Fig. 7), as previously reported in H<sub>2</sub>O<sub>2</sub>-treated cells (50). Although positioned nucleosomes were also observed in  $slm9\Delta$  cells, decreased nucleosome peaks upon stress treatment were not observed in  $slm9\Delta$  cells (Fig. 7). Considering that regulatory regions of  $ctt1^+$  gene such as TATA box and Atf1 binding site are located in close proximity to the TSS (55) and overlapped with +1 nucleosome position (Fig. 7), it seems that HIRA is required for recruitment of Pol II to these regulatory regions. Furthermore, nucleosomes downstream of TSS are also altered in *slm*9 $\Delta$  cells (Fig. 7), consistent with the result of ChIP assay detecting impaired Pol II recruitment to ORFs of CESR genes (Fig. 5B). Taken together, these results suggest that HIRA is required for nucleosome eviction to regulate Pol II accessibility and/or progression, and expression of stress-responsive genes.

Priming stress facilitates expression of stress-responsive genes under subsequent severe stress- As HIRA plays a role in the transcriptional control of stress-responsive genes under the stress conditions, we characterized the expression of several CESR genes ( $ctt1^+$ ,  $gpx1^+$ , and  $hsp9^+$ ) in the wild-type cells during cross tolerance by quantitative RT-PCR. We found that the severe stress alone induced only less than threefold increase in CESR gene expression (Fig. 8A). In contrast, when the cells were treated with the priming stress prior to the severe stress, the expression of those genes increased dramatically (Fig. 8A). Furthermore, the fold change relative to the control condition of CESR gene expression in the wild-type cells under the stress conditions was plotted using microarray data. Similar to the results of quantitative RT-PCR (Fig. 8A), the fold change of CESR gene expression under the severe stress condition showed a dramatic increase when the cells were exposed to the priming stress (Fig. 8B). These findings indicate that the priming stress enhanced stress-responsive gene expression and as a result, the cells acquired resistance to impending stress.

## DISCUSSION

We have demonstrated that the fission yeast HIRA complex is involved in cross tolerance. We also found that in the cross tolerance, the expression levels of stress-responsive genes under the severe stress was augmented when the cells were exposed to the priming stress. Although the fission yeast HIRA has been shown to be implicated in gene silencing and the heterochromatin assembly (26,38,40,56), our results showed that the fission yeast HIRA is required for the transcriptional activation of stress-responsive genes under the low-dose stress conditions. Therefore, HIRA would regulate transcription both positively and negatively.

HIRA disruption decreased stress-responsive

gene expression under the priming stress condition (Fig. 5A, Tables 2 and 3). As the expression of stress-responsive genes under the severe stress was enhanced by the priming stress (Fig. 8), the defect of the cross tolerance in the HIRA disruptants may have come from the impaired expression of those genes during the priming stress. Thus, cells may stimulate stress-responsive gene expression under the low-dose stress conditions to deal with stress and to prepare for future stress, consistent with a previous report of the budding yeast (7). In contrast, severe stress alone increased stress-responsive gene expression in  $slm9\Delta$  and  $hip1\Delta$  cells (Fig. S3 and Table S2). Considering that the severe stress alone did not lead to a marked increase of stress-responsive gene expression in the wild-type cells (Fig. 8), we speculate that the induction of those gene expression may be inhibited or occur at only a low level in the wild-type cells under the severe stress conditions. One possible explanation is that the induction of stress-responsive genes for survival would be too late after the high-dose stress, so cells may cease the transcription of those genes under the high-dose stress conditions in order not to consume extra, yet futile, energy. However, such regulation may be compromised in HIRA disruptants and this may lead to the up-regulation of stress-responsive genes. It will be important to study the dose-dependent stress response in detail to test if this hypothesis is plausible or not.

The viability of HIRA disruptants under the severe stress condition was comparable to that of the wild-type cells (Fig. 2A). Furthermore, HIRA disruptants showed high sensitivity to rather low-dose stress (Fig. 3). Thus, HIRA seems to control the transcription of stress-responsive genes specifically under low-dose stress. The accessibility of the transcription machinery is regulated by chromatin assembly and disassembly (57). Slm9 is recruited to the stress-responsive gene loci in the wild-type cells (Fig. 4B), and expression stress-responsive gene and stress-dependent Pol II enrichment are impaired in HIRA disruptants (Fig. 5). Moreover, nucleosome eviction at  $ctt1^+$  gene region upon stress treatment is hampered by slm9 disruption (Fig. 7). Taken together, HIRA likely regulates the transcription of stress-responsive genes through the eviction of histones. In addition, the position of nucleosomes was slightly different between wild-type and  $slm9\Delta$  cells (Fig. 7). Although the significance of this displacement is unclear, it may contribute to

the accessibility of proteins involved in transcription. Thus, HIRA may also have a role in the regulation of nucleosome positioning. One recent study has shown that histone H3 acetyltransferase Gcn5 facilitates Pol Π progression along stress-responsive genes in fission yeast (50). Therefore, both HIRA and Gcn5 should stimulate the eviction of histones at these loci to allow Pol II to progress, and stress-responsive gene expression is induced by stress-activated MAPK Spc1 and its downstream transcription factor Atf1 to respond to stress.

One possible factor that enhances the recruitment of HIRA and Gcn5 may be the 19S ATPase subunits of the proteasome. Mass spectrometric analysis of the fission yeast Slm9 has led to the identification of the 19S ATPase complex as the interacting proteins (27). The 19S ATPase complex is recruited to chromatin in a histone H2B ubiquitylation-dependent manner and plays a nonproteolytic role in Pol II transcriptional elongation in the budding yeast (58-60). Moreover, in the fission yeast, histone H2B ubiquitylation is required for transcriptional elongation and HIRA mutations are synthetically lethal with htb1-K119R, the mutation in the conserved ubiquitin acceptor site of histone H2B, indicating the role of histone H2B ubiquitylation in chromatin assembly during transcription (61). Indeed, the overexpression of ubiquitin-conjugating enzyme gene confers enhanced stress tolerance in plants (62) and RAD6, which encodes ubiquitin-conjugating enzyme in the budding yeast, is involved in the heat shock induction of bleomycin resistance (cross tolerance) (63). Transcriptional regulation through HIRA recruitment may be required for not only stress response but also other biological responses in general. For instance, a recent study has revealed that Hip3, a component of the HIRA complex, is engaged in the repression of meiosis-specific gene SPCC663.14c expression under the vegetative state (56). Considering that Slm9 recruitment to stress-responsive gene loci depends on Atf1 (Fig. 4B), other factors, such as transcription factor which function together with general factors including HIRA, may determine the specificity of the response. In this way, HIRA may stimulate or repress transcription via mediation of nucleosome states, depending on the situation. Thus, it will be important to reveal the relationship among all these factors as they may cooperatively regulate stress-responsive gene expression.

## REFERENCES

- 1. Hahn, G. M., Ning, S. C., Elizaga, M., Kapp, D. S., and Anderson, R. L. (1989) *Int J Radiat Biol* 56, 817-825
- 2. Davies, J. M., Lowry, C. V., and Davies, K. J. (1995) Arch Biochem Biophys 317, 1-6
- 3. Yonezawa, M., Misonoh, J., and Hosokawa, Y. (1996) *Mutat Res* **358**, 237-243
- 4. Hengge-Aronis, R., Lange, R., Henneberg, N., and Fischer, D. (1993) J Bacteriol 175, 259-265
- 5. Santos, B. C., Chevaile, A., Kojima, R., and Gullans, S. R. (1998) Am J Physiol 274, F1054-1061
- 6. Larkindale, J., and Huang, B. (2004) J Plant Physiol 161, 405-413
- 7. Berry, D. B., and Gasch, A. P. (2008) Mol Biol Cell 19, 4580-4587
- 8. Moskalev, A., Shaposhnikov, M., and Turysheva, E. (2009) *Biogerontology* 10, 3-11
- 9. Calabrese, E. J., and Baldwin, L. A. (1999) *Toxicol Pathol* 27, 195-216
- 10. Calabrese, E. J., and Baldwin, L. A. (2001) Crit Rev Toxicol 31, 353-424
- 11. Rattan, S. I. (2008) Ageing Res Rev 7, 63-78
- 12. Gems, D., and Partridge, L. (2008) Cell Metab 7, 200-203
- 13. Shiozaki, K., and Russell, P. (1995) Nature 378, 739-743
- 14. Millar, J. B., Buck, V., and Wilkinson, M. G. (1995) Genes Dev 9, 2117-2130
- 15. Degols, G., Shiozaki, K., and Russell, P. (1996) *Mol Cell Biol* 16, 2870-2877
- 16. Degols, G., and Russell, P. (1997) Mol Cell Biol 17, 3356-3363
- 17. Chen, D., Toone, W. M., Mata, J., Lyne, R., Burns, G., Kivinen, K., Brazma, A., Jones, N., and Bahler, J. (2003) *Mol Biol Cell* 14, 214-229
- 18. Avvakumov, N., Nourani, A., and Cote, J. (2011) Mol Cell 41, 502-514
- 19. Kirov, N., Shtilbans, A., and Rushlow, C. (1998) *Gene* **212**, 323-332
- 20. Lamour, V., Lecluse, Y., Desmaze, C., Spector, M., Bodescot, M., Aurias, A., Osley, M. A., and Lipinski, M. (1995) *Hum Mol Genet* **4**, 791-799
- 21. Scamps, C., Lorain, S., Lamour, V., and Lipinski, M. (1996) Biochim Biophys Acta 1306, 5-8
- 22. Roberts, C., Daw, S. C., Halford, S., and Scambler, P. J. (1997) Hum Mol Genet 6, 237-245
- 23. Kanoh, J., and Russell, P. (2000) Genetics 155, 623-631
- 24. Blackwell, C., Martin, K. A., Greenall, A., Pidoux, A., Allshire, R. C., and Whitehall, S. K. (2004) *Mol Cell Biol* 24, 4309-4320
- 25. Sherwood, P. W., Tsang, S. V., and Osley, M. A. (1993) *Mol Cell Biol* 13, 28-38
- 26. Greenall, A., Williams, E. S., Martin, K. A., Palmer, J. M., Gray, J., Liu, C., and Whitehall, S. K. (2006) *J Biol Chem* **281**, 8732-8739
- 27. Anderson, H. E., Kagansky, A., Wardle, J., Rappsilber, J., Allshire, R. C., and Whitehall, S. K. (2010) *PLoS One* **5**, e13488
- 28. Balaji, S., Iyer, L. M., and Aravind, L. (2009) Mol Biosyst 5, 269-275
- 29. Banumathy, G., Somaiah, N., Zhang, R., Tang, Y., Hoffmann, J., Andrake, M., Ceulemans, H., Schultz, D., Marmorstein, R., and Adams, P. D. (2009) *Mol Cell Biol* **29**, 758-770
- 30. Rai, T. S., Puri, A., McBryan, T., Hoffman, J., Tang, Y., Pchelintsev, N. A., van Tuyn, J., Marmorstein, R., Schultz, D. C., and Adams, P. D. (2011) *Mol Cell Biol* **31**, 4107-4118
- 31. Ray-Gallet, D., Quivy, J. P., Scamps, C., Martini, E. M., Lipinski, M., and Almouzni, G. (2002) *Mol Cell* **9**, 1091-1100
- 32. Green, E. M., Antczak, A. J., Bailey, A. O., Franco, A. A., Wu, K. J., Yates, J. R., 3rd, and Kaufman, P. D. (2005) *Curr Biol* **15**, 2044-2049
- 33. Tagami, H., Ray-Gallet, D., Almouzni, G., and Nakatani, Y. (2004) Cell 116, 51-61
- 34. Smith, S., and Stillman, B. (1989) Cell 58, 15-25
- 35. Spector, M. S., Raff, A., DeSilva, H., Lee, K., and Osley, M. A. (1997) Mol Cell Biol 17, 545-552
- 36. Prochasson, P., Florens, L., Swanson, S. K., Washburn, M. P., and Workman, J. L. (2005) *Genes Dev* **19**, 2534-2539
- 37. Nelson, D. M., Ye, X., Hall, C., Santos, H., Ma, T., Kao, G. D., Yen, T. J., Harper, J. W., and Adams, P. D. (2002) *Mol Cell Biol* **22**, 7459-7472
- 38. Anderson, H. E., Wardle, J., Korkut, S. V., Murton, H. E., Lopez-Maury, L., Bahler, J., and

Whitehall, S. K. (2009) Mol Cell Biol 29, 5158-5167

- Zhang, R., Poustovoitov, M. V., Ye, X., Santos, H. A., Chen, W., Daganzo, S. M., Erzberger, J. P., Serebriiskii, I. G., Canutescu, A. A., Dunbrack, R. L., Pehrson, J. R., Berger, J. M., Kaufman, P. D., and Adams, P. D. (2005) *Dev Cell* 8, 19-30
- 40. Yamane, K., Mizuguchi, T., Cui, B., Zofall, M., Noma, K., and Grewal, S. I. (2011) *Mol Cell* **41**, 56-66
- 41. Ahmad, A., Kikuchi, H., Takami, Y., and Nakayama, T. (2005) *J Biol Chem* **280**, 32090-32100
- 42. Formosa, T., Ruone, S., Adams, M. D., Olsen, A. E., Eriksson, P., Yu, Y., Rhoades, A. R., Kaufman, P. D., and Stillman, D. J. (2002) *Genetics* **162**, 1557-1571
- 43. Ahmad, K., and Henikoff, S. (2002) Mol Cell 9, 1191-1200
- 44. Mito, Y., Henikoff, J. G., and Henikoff, S. (2005) *Nat Genet* **37**, 1090-1097
- 45. Moreno, S., Klar, A., and Nurse, P. (1991) *Methods Enzymol* **194**, 795-823
- 46. Alfa, C., Fantes, P., Hyams, J., McLeod, M., and Warbrick, E. (1993) Cold Spring Harbor Laboratory Press
- 47. Kanoh, J., Sugimoto, A., and Yamamoto, M. (1995) *Mol Biol Cell* **6**, 1185-1195
- 48. Lantermann, A., Stralfors, A., Fagerstrom-Billai, F., Korber, P., and Ekwall, K. (2009) *Methods* 48, 218-225
- 49. Sekinger, E. A., Moqtaderi, Z., and Struhl, K. (2005) Mol Cell 18, 735-748
- 50. Sanso, M., Vargas-Perez, I., Quintales, L., Antequera, F., Ayte, J., and Hidalgo, E. (2011) *Nucleic Acids Res* **39**, 6369-6379
- 51. Lantermann, A. B., Straub, T., Stralfors, A., Yuan, G. C., Ekwall, K., and Korber, P. (2010) *Nat Struct Mol Biol* **17**, 251-257
- 52. Dohke, K., Miyazaki, S., Tanaka, K., Urano, T., Grewal, S. I., and Murakami, Y. (2008) *Genes Cells* **13**, 1027-1043
- 53. Mosammaparast, N., Ewart, C. S., and Pemberton, L. F. (2002) *EMBO J* 21, 6527-6538
- 54. Chen, D., Wilkinson, C. R., Watt, S., Penkett, C. J., Toone, W. M., Jones, N., and Bahler, J. (2008) *Mol Biol Cell* **19**, 308-317
- 55. Nakagawa, C. W., Yamada, K., and Mutoh, N. (2000) J Biochem 127, 233-238
- 56. Mizuki, F., Tanaka, A., Hirose, Y., and Ohkuma, Y. (2011) *PLoS One* 6, e19442
- 57. Williams, S. K., and Tyler, J. K. (2007) Curr Opin Genet Dev 17, 88-93
- 58. Ferdous, A., Gonzalez, F., Sun, L., Kodadek, T., and Johnston, S. A. (2001) Mol Cell 7, 981-991
- 59. Gonzalez, F., Delahodde, A., Kodadek, T., and Johnston, S. A. (2002) Science 296, 548-550
- 60. Ezhkova, E., and Tansey, W. P. (2004) Mol Cell 13, 435-442
- 61. Tanny, J. C., Erdjument-Bromage, H., Tempst, P., and Allis, C. D. (2007) Genes Dev 21, 835-847
- 62. Zhou, G. A., Chang, R. Z., and Qiu, L. J. (2010) Plant Mol Biol 72, 357-367
- 63. Keszenman, D. J., Candreva, E. C., Sanchez, A. G., and Nunes, E. (2005) *Environ Mol Mutagen* **45**, 36-43

Acknowledgments- We are grateful to Dr. Yukinobu Nakaseko for useful discussion and critical reading of the manuscript. We thank Drs. Fumihiko Sato, Peter Baumann, and Junko Kanoh for warm encouragement and valuable suggestions, and Dr. Taro Nakamura, RIKEN Bioresource Center, for providing the *S. pombe* genomic library (pTN-L1).

## FOOTNOTES

\*This work was supported by a Grant-in-Aid for Cancer Research from the Ministry of Education, Culture, Sports, Science, and Technology, Japan (to F.I.). M.C. is a recipient of a fellowship from the Japan Society for the Promotion of Science (JSPS).

<sup>1</sup>To whom correspondence should be addressed: Fuyuki Ishikawa, Kyoto University, Yoshida-Konoe-cho, Sakyo-ku, Kyoto 606-8501, Japan, Tel: +81 75 753 4195; Fax: +81 75 753 4197; E-mail: <u>fishikaw@lif.kyoto-u.ac.jp</u>

<sup>2</sup>The abbreviations used are: CESR, core environmental stress response; GO, gene ontology; MNase, micrococcal nuclease; NDR, nucleosome depleted region; Pol II, RNA polymerase II; TSS, transcription

start site

## FIGURE LEGENDS

## Figure 1. Various stress combinations induce cross tolerance in the fission yeast.

Viability of wild-type (JK317) cells following exposure to indicated stress is shown. Priming stress was 40°C, 0.6 M KCl, or 0.1 mM H<sub>2</sub>O<sub>2</sub> for 1 h and severe stress was 46°C, 2.4 M KCl, or 25 mM H<sub>2</sub>O<sub>2</sub> for 1 h. Results are means of at least four independent experiments and error bars represent standard error. Significant difference between viabilities with or without priming stress was determined by the Student's *t*-test (\* P<0.05, \*\* P<0.01).

## Figure 2. HIRA complex is required for cross tolerance.

The viability of the indicated cells following exposure to cross (acquired)-tolerance-inducible stress is shown. Results are means of at least three independent experiments and error bars represent standard error. (A, B, E) Cells were subjected to 40°C for 1 h (priming stress) and 25 mM  $H_2O_2$  for another 1 h (severe stress). (C) Oxidative and heat stresses: cells were subjected to 0.1 mM  $H_2O_2$  for 1 h (priming stress) and 46°C for another 1 h (severe stress). Osmotic and oxidative stresses: cells were subjected to 0.6 M KCl for 1 h (priming stress) and 25 mM  $H_2O_2$  for 1 h (priming stress) and 25 mM  $H_2O_2$  for another 1 h (severe stress). (D) Cells were subjected to 0.1 mM  $H_2O_2$  for 1 h (priming stress) and 25 mM  $H_2O_2$  for another 1 h (severe stress).

## Figure 3. HIRA complex mutants are especially sensitive to low-dose stress.

Tenfold serial dilutions of wild-type (JK317),  $slm9\Delta$  (MC3749),  $hip1\Delta$  (MC3725),  $hip3\Delta$  (MC3773),  $hip4\Delta$  (MC3799), and  $spc1\Delta$  (MC3801) cells were spotted onto YES plates or YES plates containing H<sub>2</sub>O<sub>2</sub>, menadione, KCl, or sorbitol. For heat stress, the spotted YES plates were subjected to the indicated heat stress dose.

## Figure 4. HIRA is recruited to stress-responsive gene loci upon stress treatment.

(A) slm9-12myc (MC3793) and hip1-12myc (MC3795) cells were exposed to 40°C for the indicated times. Whole cell extracts were prepared and analyzed by Western blotting with anti-Myc and anti-Cdc2 (control) antibodies. (B) slm9-12myc (MC3793) and slm9-12myc  $atf1\Delta$  (MC4219) cells were exposed or not exposed to 40°C for 15 min. ChIP assay using anti-Myc antibody was performed. Purified DNA was analyzed by real-time PCR using primer sets for the promoter (prom) and coding (ORF) regions of stress-responsive genes ( $ctt1^+$ ,  $gpx1^+$ , and  $hsp9^+$ ), non-stress-responsive gene ( $pol1^+$ ), and heterochromatic locus (outer repeats of centromere, dh). Values shown were normalized to  $cdc2^+$  promoter. Results are means of three independent experiments and error bars represent standard error.

## Figure 5. HIRA is required for stress-responsive gene expression and Pol II recruitment.

(A) Wild-type (JK317),  $slm9\Delta$  (MC3749), and  $hip1\Delta$  (MC3725) cells were exposed or not exposed to 40°C for 1 h. Total RNA was analyzed by RT-PCR using primer sets for stress-responsive genes ( $ctt1^+$ ,  $gpx1^+$ ,  $gpd1^+$ ,  $tps1^+$ ,  $hsp9^+$ , and  $hsp16^+$ ).  $act1^+$  is shown as loading control. (B) Wild-type (JK317) and  $slm9\Delta$  (MC3749) cells were exposed or not exposed to 40°C for 15 min. ChIP assay using anti-Pol II antibodies was performed. Purified DNA was analyzed in the same way as described in Fig. 4B. Results are means of three independent experiments and error bars represent standard error.

## Figure 6. HIRA disruption mainly affects stress-responsive gene expression.

(A, B, C) Fold change of gene expression under priming stress (40°C for 1 h) condition compared to no stress condition is plotted for wild-type (JK317),  $slm9\Delta$  (MC3749), and  $hip1\Delta$  (MC3725) cells. Horizontal bars represent means of fold change and mean values are shown below the abscissa axis. Fold change in expression of all genes (A), CESR genes (B), and genes whose expression was increased more than twofold in wild-type cells (C) is shown. Significant difference in expression between wild-type and mutant cells was determined by the Student's *t*-test (\* P<0.05, \*\* P<0.01).

## Figure 7. HIRA is required for nucleosome eviction at stress-responsive gene locus.

Wild-type (JK317) and  $slm9\Delta$  (MC3749) cells were exposed or not exposed to 40°C for 15 min. Mononucleosomal DNA was isolated from the cells and nucleosome-scanning analysis was performed. Real-time PCR was carried out using 10 overlapping primer sets along  $ctt1^+$  gene. Nucleosomal DNA enrichment is defined by the ratio of the amplified products with mononucleosomal DNA to genomic DNA. Results are means of three independent experiments and error bars represent standard error. Inferred locations of nucleosomes (light gray ovals) with respect to ORF (white rectangle) and TSS (black arrow) are shown. TATA box (-30 to -23) and Atf1 binding site (-57 to -50) are also represented as black rectangle and dark gray rectangle, respectively (55).

## Figure 8. Priming stress enhances stress-responsive gene expression under severe stress.

(A) Wild-type (JK317) cells were either not exposed to stress (no stress) or exposed to various stresses: 40°C for 1 h (priming stress alone), 25 mM H<sub>2</sub>O<sub>2</sub> for 1 h (severe stress alone), or 40°C for 1 h followed by 25 mM H<sub>2</sub>O<sub>2</sub> for 1 h (priming stress followed by severe stress). Total RNA was analyzed by quantitative RT-PCR using primer sets for stress-responsive genes (*ctt1*<sup>+</sup>, *gpx1*<sup>+</sup>, and *hsp9*<sup>+</sup>) and non-stress-responsive gene (*ade6*<sup>+</sup>). Values shown were normalized to *act1*<sup>+</sup> expression. Results are means of five independent experiments and error bars represent standard error. (B) Fold change of CESR gene expression under three stress conditions compared to no stress condition is plotted for wild-type (JK317) cells. The three stress conditions are as follows: priming stress alone (40°C for 1 h, 1st), severe stress alone (25 mM H<sub>2</sub>O<sub>2</sub> for 1 h, 2nd), and priming stress followed by severe stress (40°C for 1 h followed by 25 mM H<sub>2</sub>O<sub>2</sub> for 1 h, 1st+2nd). Horizontal bars represent means of fold change and mean values are shown below the abscissa axis.

| Strain | Genotype  |
|--------|---|
| JK316  | h <sup>+</sup> leu1-32 ura4-D18   |
| JK317  | h <sup>-</sup> leu1-32 ura4-D18   |
| YT2272 | h <sup>-</sup> leu1-32 ura4-D18 spc1 ::kanMX6                                 |
| MC3725 | h <sup>-</sup> leu1-32 ura4-D18 hip1 ::ura4 <sup>+</sup>                      |
| MC3749 | h <sup>-</sup> leu1-32 ura4-D18 slm9 ::ura4 <sup>+</sup>                      |
| MC3768 | h <sup>-</sup> leu1-32 ura4-D18 pcf1 ::kanMX6                                 |
| MC3773 | h <sup>-</sup> leu1-32 ura4-D18 hip3 ::ura4 <sup>+</sup>                      |
| MC3793 | h <sup>-</sup> leu1-32 ura4-D18 slm9-12myc (ura4 <sup>+</sup> )               |
| MC3795 | h <sup>-</sup> leu1-32 ura4-D18 hip1-12myc (ura4 <sup>+</sup> )               |
| MC3797 | h <sup>-</sup> leu1-32 ura4-D18 slm9-GFP (ura4 <sup>+</sup> )                 |
| MC3799 | h <sup>-</sup> leu1-32 ura4-D18 hip4 ::ura4 <sup>+</sup>                      |
| MC3801 | h <sup>-</sup> leu1-32 ura4-D18 spc1 ::ura4 <sup>+</sup>                      |
| MC3849 | h <sup>-</sup> leu1-32 ura4-D18 nap1 ::ura4 <sup>+</sup>                      |
| MC4219 | h <sup>-</sup> leu1-32 ura4-D18 slm9-12myc (ura4 <sup>+</sup> ) atf1 ::hphMX6 |

Table 1 S. pombe strains used in this study

| CO torm                              | Number of        | % of induced  | Number of total | % of total    | n velue  |
|--------------------------------------|------------------|---------------|-----------------|---------------|----------|
|                                      | induced genes in | genes in term | genes in term   | genes in term | p-value  |
| WT                                   |                  |               |                 |               |          |
| cellular response to stress          | 115              | 72.8          | 694             | 14.1          | 9.97E-38 |
| meiosis                              | 42               | 26.6          | 353             | 7.2           | 7.26E-05 |
| cellular response to oxidative stres | 16               | 10.1          | 60              | 1.2           | 7.26E-05 |
| oxidoreductase activity              | 37               | 23.4          | 275             | 5.6           | 1.38E-04 |
| M phase                              | 42               | 26.6          | 518             | 10.5          | 2.70E-02 |
| $slm9\Delta$                         |                  |               |                 |               |          |
| cellular response to stress          | 80               | 69.0          | 694             | 14.1          | 2.20E-26 |
| meiosis                              | 43               | 37.1          | 353             | 7.2           | 1.02E-06 |
| M phase                              | 43               | 37.1          | 518             | 10.5          | 3.22E-04 |
| $hip1\Delta$                         |                  |               |                 |               |          |
| cellular response to stress          | 65               | 68.4          | 694             | 14.1          | 4.33E-19 |
| meiosis                              | 35               | 36.8          | 353             | 7.2           | 1.38E-04 |
| M phase                              | 35               | 36.8          | 518             | 10.5          | 1.25E-02 |

 Table 2 Principal gene ontology terms enriched in priming-stress-induced genes

| CO tarm   | Number of         | % of selected | Number of total | % of total    | n voluo  |
|---|-------------------|---------------|-----------------|---------------|----------|
|   | selected genes in | genes in term | genes in term   | genes in term | p-value  |
| WT fold change/slm9 $\Delta$ fold change $\geq 2$                               |                   |               |                 |               |          |
| cellular response to stress   | 47                | 92.2          | 694             | 14.1          | 1.83E-19 |
| cellular response to stimulus   | 47                | 92.2          | 730             | 14.9          | 1.83E-19 |
| response to stress  | 47                | 92.2          | 733             | 14.9          | 1.42E-18 |
| response to stimulus  | 47                | 92.2          | 819             | 16.7          | 1.68E-18 |
| oxidoreductase activity   | 15                | 29.4          | 275             | 5.6           | 3.11E-03 |
| oxidoreductase activity, acting on CH-OH group of donors                        | 2                 | 3.9           | 63              | 1.3           | 3.40E-03 |
| response to oxidative stress  | 8                 | 15.7          | 69              | 1.4           | 5.84E-03 |
| oxidation reduction   | 14                | 27.5          | 243             | 4.9           | 9.38E-03 |
| oxidoreductase activity, acting on CH-OH group of donors, NAD or NADP as accept | 2                 | 3.9           | 58              | 1.2           | 1.17E-02 |
| cellular response to oxidative stress   | 7                 | 13.7          | 60              | 1.2           | 1.33E-02 |
| WT fold change/ <i>hip1</i> $\Delta$ fold change $\geq 2$                       |                   |               |                 |               |          |
| cellular response to stress   | 52                | 74.3          | 694             | 14.1          | 3.25E-23 |
| cellular response to stimulus   | 52                | 74.3          | 730             | 14.9          | 3.25E-23 |
| response to stress  | 52                | 74.3          | 733             | 14.9          | 3.17E-22 |
| response to stimulus  | 52                | 74.3          | 819             | 16.7          | 5.27E-22 |
| oxidoreductase activity   | 16                | 22.9          | 275             | 5.6           | 1.36E-03 |
| oxidoreductase activity, acting on CH-OH group of donors                        | 2                 | 2.9           | 63              | 1.3           | 4.51E-03 |
| oxidation reduction   | 15                | 21.4          | 243             | 4.9           | 4.51E-03 |
| response to oxidative stress  | 8                 | 11.4          | 69              | 1.4           | 7.70E-03 |
| oxidoreductase activity, acting on CH-OH group of donors, NAD or NADP as accept | 2                 | 2.9           | 58              | 1.2           | 1.68E-02 |
| cellular response to oxidative stress   | 7                 | 10.0          | 60              | 1.2           | 1.91E-02 |

## Table 3 Gene ontology terms enriched in genes that showed WT fold change/mutant fold change≥2 under priming stress condition





# Figure 3



A





# Figure 5













В



## **Supplemental Information**

## HIRA, a conserved histone chaperone plays an essential role in low-dose stress response via transcriptional stimulation in fission yeast

Moeko Chujo<sup>1</sup>, Yusuke Tarumoto<sup>1</sup>, Koichi Miyatake<sup>2</sup>, Eisuke Nishida<sup>2</sup>, and Fuyuki Ishikawa<sup>1</sup>

From the Departments of <sup>1</sup>Gene Mechanisms and <sup>2</sup>Cell and Developmental Biology, Graduate School of Biostudies, Kyoto University, Yoshida-Konoe-cho, Sakyo-ku, Kyoto 606-8501, Japan

## Figure S1



## Figure S1. Characterization of cross-tolerance-defective mutant, 7-4.

(A) Viability of wild-type (JK317) and 7-4 cells following exposure to 40°C for 1 h (priming stress) and 25 mM H<sub>2</sub>O<sub>2</sub> for 1 h (severe stress) is shown. Results are means of six independent experiments and error bars represent standard error. (B) Tenfold serial dilutions of wild-type (JK317), 7-4, and *spc1* $\Delta$  (YT2272) cells were spotted onto YES plates or YES plates containing CaCl<sub>2</sub>. For heat stress, the spotted YES plates were incubated at 37°C. (C) Schematic structure of Slm9 protein. Slm9 has WD40 motifs (light grey) and a C-terminal domain (dark grey) that is well-conserved among HIRA family proteins from many eukaryotes (19,24). A single nucleotide deletion occurred at nucleotide 1451 (arrowhead) in 7-4 mutant, causing the reading frame shift.



# Figure S2. Nuclear localization and chromatin association of HIRA are unaffected by stress treatment.

(A) Wild-type (JK317) and *slm9-GFP* (MC3797) cells were grown in YES medium at 32°C and exposed or not exposed to 40°C for 1 h. Cells were washed with PBS and living cells in PBS were observed without fixation under a DeltaVision microscope (Applied Precision). (B) Procedure for the chromatin fractionation assay used in this study. (C) *slm9-12myc* (MC3793) and *hip1-12myc* (MC3795) cells were exposed or not exposed to 40°C for 1 h. Chromatin fractionation assay was performed as shown in (B). Proteins from each fraction were analyzed by Western blotting with anti-Myc, anti-histone H3, and anti- $\alpha$ -tubulin antibodies. The soluble fraction contains nucleoplasmic and cytoplasmic proteins, and the MNase fraction and the chromatin fraction contain chromatin-bound proteins. Histone H3 and  $\alpha$ -tubulin were used as controls for the chromatin-bound fractions and the soluble fraction, respectively. W, whole cell extract; S, soluble fraction; M, MNase fraction; C, chromatin fraction; P, pellet fraction.



## Figure S3. CESR gene expression is augmented under severe stress in HIRA disruptants.

Wild-type (JK317),  $slm9\Delta$  (MC3749), and  $hip1\Delta$  (MC3725) cells were either not exposed to stress (no stress) or exposed to various stresses: 40°C for 1 h (priming stress alone), 40°C for 1 h followed by 25 mM H<sub>2</sub>O<sub>2</sub> for 1 h (priming stress followed by severe stress), or 25 mM H<sub>2</sub>O<sub>2</sub> for 1 h (severe stress alone). Total RNA was analyzed by RT-PCR using primer sets for stress-responsive genes (*ctt1*<sup>+</sup> and *gpx1*<sup>+</sup>). *act1*<sup>+</sup> is shown as loading control.  $s\Delta$ ,  $slm9\Delta$ ;  $h\Delta$ ,  $hip1\Delta$ .

## Figure S4



## Figure S4. Gene expression in *slm9* $\Delta$ and *hip1* $\Delta$ cells shows strong correlation.

Microarray analysis was performed for wild-type (JK317),  $slm9\Delta$  (MC3749), and  $hip1\Delta$  (MC3725) cells under four conditions: control (No stress), priming stress alone (40°C for 1 h, 1st), priming stress followed by severe stress (40°C for 1 h followed by 25 mM H<sub>2</sub>O<sub>2</sub> for 1 h, 1st+2nd), and severe stress alone (25 mM H<sub>2</sub>O<sub>2</sub> for 1 h, 2nd). Pearson' s correlation coefficient (r<sup>2</sup>) was calculated for each pair of arrays and shown as a heat map. W, wild-type; S,  $slm9\Delta$ ; H,  $hip1\Delta$ .

 Table S1 Primers for real-time PCR

| Locus           | Forward primer                      | Reverse primer                           |
|-----------------|-------------------------------------|--|
| act1 (ORF)      | 5'-AGCGTGGTTATACTTTCTCTACT-3'       | 5'-GGAGGAAGATTGAGCAGCAG-3'               |
| ade6 (ORF)      | 5'-GAAAGATGCTGCCGTCATTTTAG-3'       | 5'-GCTGCGGTACGAGCATAAGTAAC-3'            |
| cdc2 (promoter) | 5'-ACATGAAGCGCTAGCCCTAAGTT-3'       | 5'-TCAACTAGCGATAGACTAGTGGAAACGCAGAGGA-3' |
| pol1 (ORF)      | 5'-AAGACGGTCTGCAAGAAGAATCTC-3'      | 5'-GCTCAAAAACCAATCCACCTTT-3'             |
| ctt1 (promoter) | 5'-CGCTAATAATGATGCTCTTTGGC-3'       | 5'-CAATAGGAAAACTCTTACCAACGC-3'           |
| ctt1 (ORF)      | 5'-AAGAACGTTGCCGGTCACTT-3'          | 5'-TGGCGTTCACGTACAGGAGAT-3'              |
| gpx1 (promoter) | 5'-TGTTGTAACTAACGCAAACTACTTAATCG-3' | 5'-GGCTGAGACTCATACTTAAACAGTATAGGTATC-3'  |
| gpx1 (ORF)      | 5'-AAGATCAATGTTAATGGCGACAAC-3'      | 5'-GATGACTTGACCTTGACGATTGAC-3'           |
| hsp9 (promoter) | 5'-CGAATGGTGCGAAGAAAAGG-3'          | 5'-GCTCGCTATCCAATCAGACAAA-3'             |
| hsp9 (ORF)      | 5'-AAGGTCGCCTCTGCTTTTACC-3'         | 5'-AGCGTTGAGCCTTGTCATGAG-3'              |
| dh              | 5'-AACAAAGCGACAATAGCAGTC-3'         | 5'-TAGCTTGTTGACATAATGAAGACCAA-3'         |
| ctt1-1          | 5'-GATGCTCTTTGGCTCACTAAGC-3'        | 5'-TGTAGAATTACCAACGTCATATTTGC-3'         |
| ctt1-2          | 5'-TGGAATCTCGGCCATTTG-3'            | 5'-TATATTCAAGCAACTTGCAATTG-3'            |
| ctt1-3          | 5'-AATTGCAAGTTGCTTGAATATACAGC-3'    | 5'-GAACAAGGGAATTACAATCACACAC-3'          |
| ctt1-4          | 5'-TGTGTGTGATTGTAATTCCCTTG-3'       | 5'-AAAAAGACAGTCAAAAAATTGTGTT-3'          |
| ctt1-5          | 5'-GACTGTCTTTTTTTTTTCCCCTCC-3'      | 5'-GAGCAAATGATTTTAAACTAGCTTGTC-3'        |
| ctt1-6          | 5'-AGCTAGTTTAAAATCATTTGCTCG-3'      | 5'-TTCGCTGATGTTTGAATCCTTAG-3'            |
| ctt1-7          | 5'-GGATTCAAACATCAGCGAAATG-3'        | 5'-TTACCCACACGAGCCGCA-3'                 |
| ctt1-8          | 5'-CTGCGGCTCGTGTGGGTA-3'            | 5'-CAGGAATACGCTCGCGATC-3'                |
| ctt1-9          | 5'-CATTTAATCGACGTCTTTCAACAC-3'      | 5'-CGGTGCATTCGAATTCACC-3'                |
| ctt1-10         | 5'-CATGCAAAGGGTTCCGGT-3'            | 5'-TAGGGGTTTTCTTACCAACCTTAG-3'           |

#### Table S2 Gene ontology terms enriched in stress-induced genes

|                  |   | Number of        | % of induced                                | Number of total | % of total    |                      |
|------------------|---|------------------|---|-----------------|---------------|----------------------|
| Stress condition | GO term   | induced genes in | genes in term                               | genes in term   | genes in term | p-value              |
| priming stress   | WT  |                  | 2910 D. |                 |               |                      |
| alone            | cellular response to stress   | 115              | 72.8  | 694             | 14.1          | 9.97E-38             |
|                  | cellular response to stimulus   | 115              | 72.8  | 730             | 14.9          | 1.24E-37             |
|                  | response to stress  | 118              | 74.7  | 733             | 14.9          | 2.56E-35             |
|                  | response to stimulus  | 118              | 74.7  | 819             | 16.7          | 2.90E-33             |
|                  | response to oxidative stress  | 17               | 10.8  | 69              | 1.4           | 3.08E-05             |
|                  | meiosis   | 42               | 26.6  | 353             | 7.2           | 7.26E-05             |
|                  | cellular response to oxidative stress   | 16               | 10.1  | 60              | 1.2           | 7.26E-05             |
|                  | M phase of meiotic cell cycle   | 42               | 26.6  | 353             | 7.2           | 7.26E-05             |
|                  | meiotic cell cycle  | 42               | 26.6  | 355             | 7.2           | 7.49E-05             |
|                  | oxidoreductase activity   | 37               | 23.4  | 275             | 5.6           | 1.38E-04             |
|                  | cellular response to chemical stimulus  | 16               | 10.1  | 119             | 2.4           | 2.10E-03             |
|                  | oxidereductese activity acting on CH OH group of denors                           | 34               | 21.5  | 243<br>63       | 4.9           | 2.81E-03             |
|                  | oxidoreductase activity, acting on CH-OH group of donors NAD or NADP as accepted  | 2                | 1.9   | 58              | 1.5           | 5.38E-03             |
|                  | M phase   | 42               | 26.6  | 518             | 10.5          | 2 70E-02             |
|                  | sim0 A  | 42               | 20.0  | 510             | 10.5          | 2.701 02             |
|                  | response to stress  | 83               | 71.6  | 733             | 14.9          | 2.20E-26             |
|                  | cellular response to stress   | 80               | 69.0  | 694             | 14.1          | 2.20E-26             |
|                  | cellular response to stimulus   | 80               | 69.0  | 730             | 14.9          | 1.15E-24             |
|                  | response to stimulus  | 83               | 71.6  | 819             | 16.7          | 8.79E-23             |
|                  | meiosis   | 43               | 37.1  | 353             | 7.2           | 1.02E-06             |
|                  | M phase of meiotic cell cycle   | 43               | 37.1  | 353             | 7.2           | 1.02E-06             |
|                  | meiotic cell cycle  | 43               | 37.1  | 355             | 7.2           | 1.06E-06             |
|                  | M phase   | 43               | 37.1  | 518             | 10.5          | 3.22E-04             |
|                  | cell cycle phase  | 43               | 37.1  | 550             | 11.2          | 8.97E-04             |
|                  | cell cycle process  | 43               | 37.1  | 594             | 12.1          | 2.00E-03             |
|                  | $hip1 \Delta$   | <i>c</i> 0       | 716   | 722             | 14.0          | 4 225 10             |
|                  | cellular response to stress   | 08<br>65         | /1.0  | / 33            | 14.9          | 4.35E-19<br>4.33E 10 |
|                  | cellular response to stimulus   | 65               | 00.4<br>68 /                                | 730             | 14.1          | +.55E-19<br>1 21E-17 |
|                  | response to stimulus  | 68               | 71.6  | 819             | 14.7          | 1.21E-17             |
|                  | meiosis   | 35               | 36.8  | 353             | 7.2           | 1.38E-04             |
|                  | M phase of meiotic cell cycle   | 35               | 36.8  | 353             | 7.2           | 1.38E-04             |
|                  | meiotic cell cycle  | 35               | 36.8  | 355             | 7.2           | 1.38E-04             |
|                  | M phase   | 35               | 36.8  | 518             | 10.5          | 1.25E-02             |
|                  | cell cycle phase  | 35               | 36.8  | 550             | 11.2          | 2.45E-02             |
|                  | cell cycle process  | 35               | 36.8  | 594             | 12.1          | 3.66E-02             |
| priming stress   | WT  |                  |   |                 |               |                      |
| and severe       | response to stress  | 172              | 77.5  | 733             | 14.9          | 0.00E+00             |
| stress           | cellular response to stress   | 170              | 76.6  | 694             | 14.1          | 0.00E+00             |
|                  | response to stimulus  | 172              | 77.5  | 819             | 16.7          | 0.00E+00             |
|                  | cellular response to stimulus   | 170              | 76.6  | 730             | 14.9          | 0.00E+00             |
|                  | oxidoreductase activity   | 51               | 23.0  | 275             | 5.6           | 3.40E-07             |
|                  | response to oxidative stress  | 22               | 9.9   | 69              | 1.4           | 3./0E-0/             |
|                  | cellular response to oxidative stress   | 21               | 9.5   | 00<br>242       | 1.2           | 3.20E-06             |
|                  | ovidoreductase activity acting on CH-OH group of donors                           | 45               | 20.5  | 63              | 4.9           | 5.55E-03             |
|                  | cellular response to chemical stimulus  | 21               | 9.5   | 119             | 2.4           | 9.44E-03             |
|                  | response to chemical stimulus   | 22               | 9.9   | 196             | 4.0           | 2.75E-02             |
|                  | sim9 A  |                  | ,,,   | 170             |               | 2.701 02             |
|                  | response to stress  | 153              | 90.5  | 733             | 14.9          | 0.00E+00             |
|                  | cellular response to stress   | 152              | 89.9  | 694             | 14.1          | 0.00E+00             |
|                  | response to stimulus  | 153              | 90.5  | 819             | 16.7          | 0.00E+00             |
|                  | cellular response to stimulus   | 152              | 89.9  | 730             | 14.9          | 0.00E+00             |
|                  | oxidoreductase activity   | 50               | 29.6  | 275             | 5.6           | 5.09E-10             |
|                  | oxidoreductase activity, acting on CH-OH group of donors                          | 6                | 3.6   | 63              | 1.3           | 8.76E-08             |
|                  | oxidation reduction   | 45               | 26.6  | 243             | 4.9           | 3.82E-07             |
|                  | oxidoreductase activity, acting on CH-OH group of donors, NAD or NADP as accepted | 5                | 3.0   | 58              | 1.2           | 6.79E-07             |
|                  | response to oxidative stress  | 16               | 9.5   | 69              | 1.4           | 5.42E-04             |
|                  | carbohydrate catabolic process  | 10               | 9.5   | 00<br>76        | 1.2           | 1.00E-03<br>2.12E-02 |
|                  |   | 1                | 0.0   | 70              | 1.5           | 2.12E-03             |
|                  | response to stress  | 145              | 89.0  | 733             | 14.9          | 0.00E+00             |
|                  | cellular response to stress   | 143              | 87.7  | 694             | 14.1          | 0.00E+00             |
|                  | response to stimulus  | 145              | 89.0  | 819             | 16.7          | 0.00E+00             |
|                  | cellular response to stimulus   | 143              | 87.7  | 730             | 14.9          | 0.00E+00             |
|                  | oxidoreductase activity   | 51               | 31.3  | 275             | 5.6           | 3.91E-12             |
|                  | oxidation reduction   | 46               | 28.2  | 243             | 4.9           | 7.55E-09             |
|                  | oxidoreductase activity, acting on CH-OH group of donors                          | 6                | 3.7   | 63              | 1.3           | 1.58E-08             |
|                  | oxidoreductase activity, acting on CH-OH group of donors, NAD or NADP as accepto  | 5                | 3.1   | 58              | 1.2           | 1.66E-07             |
|                  | response to oxidative stress  | 16               | 9.8   | 69              | 1.4           | 1.67E-04             |
|                  | carbohydrate catabolic process  | 1                | 0.6   | 76              | 1.5           | 7.36E-04             |
|                  | cellular response to oxidative stress   | 15               | 9.2   | 60              | 1.2           | 2.83E-03             |
| severe stress    | WI  | 25               | 07.2  |                 |               | 1.005.11             |
| alone            | cellular response to stress   | 35               | 97.2  | 694             | 14.1          | 1.28E-11             |
|                  | cellular response to stimulus   | 30<br>25         | 100.0                                       | /33             | 14.9          | 3./1E-11<br>3.71E-11 |
|                  | central response to stimulus  | 33<br>36         | 97.2<br>100.0                               | / 5U<br>810     | 14.9          | 3./1E-11<br>4.27E 10 |
|                  | elm0 A  | 30               | 100.0                                       | 017             | 10.7          | +.2/E-10             |
|                  | cellular response to stress   | 85               | 77.3  | 694             | 14.1          | 1.97E-36             |
|                  | response to stress  | 85               | 77.3  | 733             | 14.9          | 7.23E-35             |
|                  | cellular response to stimulus   | 85               | 77.3  | 730             | 14.9          | 7.23E-35             |
|                  | response to stimulus  | 85               | 77.3  | 819             | 16.7          | 8.68E-33             |
|                  | oxidoreductase activity   | 30               | 27.3  | 275             | 5.6           | 5.15E-09             |
|                  | oxidoreductase activity, acting on CH-OH group of donors                          | 4                | 3.6   | 63              | 1.3           | 3.87E-07             |

| oxidation reduction  | 27 | 24.5 | 243 | 4.9  | 2.68E-06 |
|--|----|------|-----|------|----------|
| oxidoreductase activity, acting on CH-OH group of donors, NAD or NADP as accepto | 4  | 3.6  | 58  | 1.2  | 1.04E-05 |
| response to oxidative stress   | 11 | 10.0 | 69  | 1.4  | 5.01E-04 |
| cellular response to oxidative stress  | 11 | 10.0 | 60  | 1.2  | 7.83E-04 |
| meiosis  | 25 | 22.7 | 353 | 7.2  | 2.69E-03 |
| M phase of meiotic cell cycle  | 25 | 22.7 | 353 | 7.2  | 2.69E-03 |
| meiotic cell cycle   | 25 | 22.7 | 355 | 7.2  | 2.82E-03 |
| cellular carbohydrate metabolic process  | 4  | 3.6  | 216 | 4.4  | 3.05E-02 |
| hip1 🛆   |    |      |     |      |          |
| cellular response to stress  | 78 | 80.4 | 694 | 14.1 | 1.22E-35 |
| response to stress   | 78 | 80.4 | 733 | 14.9 | 3.08E-34 |
| cellular response to stimulus  | 78 | 80.4 | 730 | 14.9 | 3.08E-34 |
| response to stimulus   | 78 | 80.4 | 819 | 16.7 | 1.34E-31 |
| oxidoreductase activity  | 27 | 27.8 | 275 | 5.6  | 1.01E-08 |
| oxidoreductase activity, acting on CH-OH group of donors                         | 4  | 4.1  | 63  | 1.3  | 5.41E-06 |
| oxidation reduction  | 24 | 24.7 | 243 | 4.9  | 9.43E-06 |
| response to oxidative stress   | 11 | 11.3 | 69  | 1.4  | 9.77E-05 |
| oxidoreductase activity, acting on CH-OH group of donors, NAD or NADP as accept  | 4  | 4.1  | 58  | 1.2  | 1.09E-04 |
| cellular response to oxidative stress  | 11 | 11.3 | 60  | 1.2  | 1.45E-04 |
| cellular carbohydrate metabolic process  | 4  | 4.1  | 216 | 4.4  | 4.37E-03 |
| carbohydrate metabolic process   | 8  | 8.2  | 226 | 4.6  | 7.45E-03 |
| monosaccharide metabolic process   | 2  | 2.1  | 68  | 1.4  | 1.93E-02 |
| glucose metabolic process  | 2  | 2.1  | 42  | 0.9  | 2.73E-02 |
| alcohol metabolic process  | 3  | 3.1  | 145 | 3.0  | 2.73E-02 |

|--|

| Table 55 Gene    | so i  | Number of          | % of repressed | Number of total | % of total    |                       |
|------------------|---|--------------------|----------------|-----------------|---------------|-----------------------|
| stress condition |   | repressed genes in | genes in term  | genes in term   | genes in term | p-value               |
| priming stress   | WT  | 15                 | 22.2           | 40              | 1.0           | 2 (0E 07              |
| alone            | cell wall   | 13                 | 33.3<br>28.9   | 48              | 1.0           | 2.69E-07<br>2.69E-07  |
|                  | external encapsulating structure                                | 13                 | 28.9           | 58              | 1.2           | 2.69E-07              |
|                  | cell surface  | 14                 | 31.1           | 111             | 2.3           | 4.54E-07              |
|                  | cell periphery  | 25                 | 55.6           | 390             | 7.9           | 9.94E-06              |
|                  | fungal-type cell wall   | 10                 | 22.2           | 36              | 0.7           | 4.46E-05              |
|                  | organic acid biosynthetic process                               | 10                 | 22.2           | 134             | 2.7           | 1.23E-03              |
|                  | plasma membrane   | 10                 | 31.1           | 234             | 4.8           | 2.39E-03              |
|                  | cellular nitrogen compound biosynthetic process                 | 10                 | 22.2           | 237             | 4.8           | 2.68E-03              |
|                  | small molecule biosynthetic process                             | 10                 | 22.2           | 307             | 6.2           | 2.68E-03              |
|                  | cellular amino acid biosynthetic process                        | 10                 | 22.2           | 104             | 2.1           | 1.42E-02              |
|                  | amine biosynthetic process                                      | 10                 | 22.2           | 112             | 2.3           | 3.09E-02              |
|                  | nydrolase activity, nydrolyzing O-glycosyl compounds            | 4                  | 8.9            | 48              | 1.0           | 3.11E-02              |
|                  | cell wall   | 10                 | 38.5           | 58              | 1.2           | 4.39E-06              |
|                  | cell surface  | 10                 | 38.5           | 111             | 2.3           | 4.39E-06              |
|                  | external encapsulating structure                                | 10                 | 38.5           | 58              | 1.2           | 4.39E-06              |
|                  | extracellular region  | 11                 | 42.3           | 48              | 1.0           | 5.18E-06              |
|                  | fungal-type cell wall   | 8                  | 30.8           | 36              | 0.7           | 5.65E-05              |
|                  | amine metabolic process   | 6                  | 23.1           | 223             | 4.5           | 1.69E-04<br>3.34E-04  |
|                  | cellular amine metabolic process                                | 6                  | 23.1           | 233             | 4.6           | 6.93E-04              |
|                  | organic acid metabolic process                                  | 6                  | 23.1           | 282             | 5.7           | 7.58E-04              |
|                  | cellular amino acid metabolic process                           | 6                  | 23.1           | 206             | 4.2           | 7.58E-04              |
|                  | carboxylic acid metabolic process                               | 6                  | 23.1           | 282             | 5.7           | 7.58E-04              |
|                  | oxoacid metabolic process                                       | 6                  | 23.1           | 282             | 5.7           | 7.58E-04              |
|                  | cytokinetic cell separation                                     | 6                  | 23.1           | 294             | 0.0           | 1.55E-03              |
|                  | organic acid biosynthetic process                               | 5                  | 19.2           | 134             | 2.7           | 1.04E-02              |
|                  | carboxylic acid biosynthetic process                            | 5                  | 19.2           | 134             | 2.7           | 1.04E-02              |
|                  | pyrimidine nucleoside metabolic process                         | 1                  | 3.8            | 10              | 0.2           | 1.68E-02              |
|                  | beta-glucosidase activity                                       | 2                  | 7.7            | 10              | 0.2           | 1.68E-02              |
|                  | cell periphery  | 10                 | 38.5           | 390<br>48       | 7.9           | 1.93E-02<br>2.30E-02  |
|                  | cytokinetic process   | 6                  | 23.1           | 108             | 2.2           | 3.08E-02              |
|                  | glucosidase activity  | 2                  | 7.7            | 23              | 0.5           | 3.63E-02              |
|                  | hip1 ∆  |                    |                |                 |               |                       |
|                  | cell wall   | 11                 | 37.9           | 58              | 1.2           | 6.39E-07              |
|                  | cell surface  | 16                 | 55.2           | 111             | 2.3           | 6.39E-07              |
|                  | extracellular region  | 11                 | 37.9           | 58<br>48        | 1.2           | 0.39E-07<br>1.00E-05  |
|                  | cellular amino acid and derivative metabolic process            | 7                  | 24.1           | 223             | 4.5           | 8.88E-05              |
|                  | fungal-type cell wall   | 8                  | 27.6           | 36              | 0.7           | 8.88E-05              |
|                  | organic acid metabolic process                                  | 7                  | 24.1           | 282             | 5.7           | 1.31E-04              |
|                  | amine metabolic process   | 7                  | 24.1           | 235             | 4.8           | 1.31E-04              |
|                  | oxoacid metabolic process                                       | 7                  | 24.1           | 282             | 5.7           | 1.31E-04<br>1.31E-04  |
|                  | cellular ketone metabolic process                               | 7                  | 24.1           | 294             | 6.0           | 2.42E-04              |
|                  | cellular amine metabolic process                                | 7                  | 24.1           | 224             | 4.6           | 2.42E-04              |
|                  | cellular amino acid metabolic process                           | 7                  | 24.1           | 206             | 4.2           | 3.06E-04              |
|                  | cytokinetic cell separation                                     | 6                  | 20.7           | 31              | 0.6           | 2.41E-03              |
|                  | organic acid biosynthetic process                               | 6                  | 20.7           | 134             | 2.7           | 3.68E-03              |
|                  | hydrolase activity, hydrolyzing O-glycosyl compounds            | 5                  | 17.2           | 48              | 1.0           | 4.40E-03              |
|                  | small molecule metabolic process                                | 8                  | 27.6           | 924             | 18.8          | 9.12E-03              |
|                  | cell periphery  | 11                 | 37.9           | 390             | 7.9           | 1.57E-02              |
|                  | hydrolase activity, acting on glycosyl bonds                    | 8                  | 27.6           | 58              | 1.2           | 1.58E-02              |
|                  | pyrimidine nucleoside metabolic process                         | 1                  | 3.4            | 10              | 0.2           | 1.80E-02              |
|                  | external side of plasma membrane                                | 2                  | 24.1           | 10<br>46        | 0.2           | 2.27E-02              |
|                  | cell wall organization or biogenesis                            | 6                  | 20.7           | 122             | 2.5           | 2.62E-02              |
|                  | cellular amino acid biosynthetic process                        | 6                  | 20.7           | 104             | 2.1           | 3.18E-02              |
|                  | glucosidase activity  | 2                  | 6.9            | 23              | 0.5           | 4.06E-02              |
|                  | small molecule biosynthetic process                             | 6                  | 20.7           | 307             | 6.2           | 4.06E-02              |
| and severe       | endoplasmic reticulum   | 103                | 33.3           | 589             | 12.0          | 6.39E-04              |
| stress           | cell division   | 59                 | 19.1           | 306             | 6.2           | 1.82E-03              |
|                  | cytokinetic process   | 12                 | 3.9            | 108             | 2.2           | 2.13E-03              |
|                  | rRNA processing   | 37                 | 12.0           | 169             | 3.4           | 2.55E-03              |
|                  | rKNA metabolic process  | 37                 | 12.0           | 170             | 3.5           | 2.55E-03              |
|                  | ribosome biogenesis   | 40                 | 14.9           | 235             | 4.8           | 2.55E-05<br>3.20E-03  |
|                  | cellular component organization or biogenesis at cellular level | 96                 | 31.1           | 1346            | 27.4          | 3.37E-03              |
|                  | cytokinetic cell separation                                     | 12                 | 3.9            | 31              | 0.6           | 3.61E-03              |
|                  | cell wall organization or biogenesis                            | 16                 | 5.2            | 122             | 2.5           | 3.78E-03              |
|                  | cellular component organization or biogenesis                   | 97                 | 31.4           | 1426            | 29.0          | 5.15E-03              |
|                  | mitotic cell cycle  | 35                 | 11.3           | 259             | 53            | 6.04E-03              |
|                  | cytokinesis   | 18                 | 5.8            | 134             | 2.7           | 7.33E-03              |
|                  | protein glycosylation   | 6                  | 1.9            | 68              | 1.4           | 7.55E-03              |
|                  | glycoprotein biosynthetic process                               | 6                  | 1.9            | 68              | 1.4           | 7.55E-03              |
|                  | macromolecule glycosylation                                     | 6                  | 1.9            | 68              | 1.4           | 7.55E-03              |
|                  | giycosyianon<br>cellular component biogenesis                   | 6<br>46            | 1.9            | 68<br>610       | 1.4<br>12.4   | 7.55E-03<br>7.9/1E-02 |
|                  | cell periphery  | -+0<br>7           | 2.3            | 390             | 7.9           | 8.25E-03              |
|                  | mitosis   | 34                 | 11.0           | 182             | 3.7           | 1.04E-02              |
|                  | glycoprotein metabolic process                                  | 6                  | 1.9            | 70              | 1.4           | 1.04E-02              |
|                  | M phase of mitotic cell cycle                                   | 34                 | 11.0           | 183             | 3.7           | 1.14E-02              |
|                  | nuclear division  | 34                 | 11.0           | 184             | 3.7           | 1.25E-02              |
|                  | manise of memorale  | 155                | 45.0           | 923             | 10.0          | 1.20E-02              |
|                  |   |                    |                |                 |               |                       |

|       | ribonucleoprotein complex biogenesis                            | 46       | 14.9         | 259        | 5.3        | 1.54E-02             |
|-------|---|----------|--------------|------------|------------|----------------------|
|       | organelle fission   | 34       | 11.0         | 188        | 3.8        | 1.92E-02             |
|       | cell wall   | 7        | 2.3          | 58         | 1.2        | 2.03E-02             |
|       | external encapsulating structure                                | 56       | 2.3          | 58<br>320  | 1.2        | 2.03E-02<br>2.28E-02 |
|       | Golgi apparatus   | 58       | 18.8         | 349        | 7.1        | 2.28E-02<br>2.28E-02 |
|       | cellular cell wall organization                                 | 16       | 5.2          | 75         | 1.5        | 2.28E-02             |
|       | cell wall organization  | 16       | 5.2          | 75         | 1.5        | 2.28E-02             |
|       | integral to membrane  | 133      | 43.0         | 909        | 18.5       | 2.34E-02             |
|       | ncking processing   | 37       | 5.2          | 240<br>76  | 5.0        | 2.54E-02<br>2.54E-02 |
|       | cell surface  | 18       | 5.8          | 111        | 2.3        | 2.64E-02             |
|       | nuclear lumen   | 56       | 18.1         | 547        | 11.1       | 3.10E-02             |
|       | cell septum   | 3        | 1.0          | 239        | 4.9        | 4.73E-02             |
|       | $slm9\Delta$  | 20       | 19.6         | 169        | 3.4        | 7 55E-06             |
|       | rRNA metabolic process  | 29       | 19.6         | 170        | 3.5        | 7.55E-06             |
|       | ribosome biogenesis   | 35       | 23.6         | 235        | 4.8        | 1.68E-05             |
|       | ncRNA processing  | 29       | 19.6         | 246        | 5.0        | 4.81E-05             |
|       | cell division   | 40       | 27.0         | 306        | 6.2        | 8.80E-05             |
|       | nucleolus   | 42       | 23.0         | 320        | 5.5        | 2.43E-04             |
|       | cellular component biogenesis at cellular level                 | 35       | 23.6         | 338        | 6.9        | 3.95E-04             |
|       | cytokinetic process   | 9        | 6.1          | 108        | 2.2        | 4.45E-04             |
|       | ncRNA metabolic process   | 29       | 19.6         | 286        | 5.8        | 4.45E-04             |
|       | cellular component biogenesis                                   | 35       | 23.6         | 610<br>547 | 12.4       | 4.64E-04<br>9.72E-04 |
|       | cytokinesis   | 42       | 9.5          | 134        | 2.7        | 1.19E-03             |
|       | extracellular region  | 13       | 8.8          | 48         | 1.0        | 3.29E-03             |
|       | cell wall   | 12       | 8.1          | 58         | 1.2        | 5.30E-03             |
|       | external encapsulating structure                                | 12       | 8.1          | 58         | 1.2        | 5.30E-03             |
|       | cytokinetic cell separation                                     | 9        | 6.1<br>8.1   | 31         | 0.6        | 6.88E-03<br>9.74E-03 |
|       | cell surface  | 12       | 9.5          | 111        | 2.3        | 2.20E-02             |
|       | fungal-type cell wall   | 9        | 6.1          | 36         | 0.7        | 2.56E-02             |
|       | cellular component organization or biogenesis                   | 36       | 24.3         | 1426       | 29.0       | 3.41E-02             |
|       | organelle lumen   | 42       | 28.4         | 717        | 14.6       | 3.42E-02             |
|       | endoplasmic reticulum   | 42<br>56 | 28.4<br>37.8 | 589        | 14.6       | 3.42E-02<br>4.65E-02 |
|       | hip1 A  | 20       | 5710         | 507        | 12:0       | 1002 02              |
|       | cell surface  | 18       | 13.6         | 111        | 2.3        | 1.68E-04             |
|       | cell division   | 36       | 27.3         | 306        | 6.2        | 1.68E-04             |
|       | cell wall   | 12       | 9.1          | 58         | 1.2        | 6.28E-04             |
|       | cell periphery  | 28       | 21.2         | 390        | 7.9        | 6.28E-04             |
|       | rRNA processing   | 23       | 17.4         | 169        | 3.4        | 1.37E-03             |
|       | rRNA metabolic process  | 23       | 17.4         | 170        | 3.5        | 1.37E-03             |
|       | cytokinetic process   | 8        | 6.1          | 108        | 2.2        | 1.37E-03             |
|       | ncKNA processing  | 23       | 17.4         | 246        | 5.0        | 1.3/E-03<br>2.43E-03 |
|       | endoplasmic reticulum   | 56       | 42.4         | 589        | 12.0       | 2.43E-03             |
|       | extracellular region  | 12       | 9.1          | 48         | 1.0        | 6.10E-03             |
|       | ribosome biogenesis   | 27       | 20.5         | 235        | 4.8        | 6.10E-03             |
|       | cell wall organization or biogenesis                            | 11       | 8.3          | 122        | 2.5        | 6.10E-03             |
|       | nckina metabolic process  | 23<br>19 | 17.4         | 280        | 5.8<br>4.8 | 0.54E-05<br>1 38E-02 |
|       | cellular cell wall organization or biogenesis                   | 11       | 8.3          | 120        | 2.4        | 1.39E-02             |
|       | cellular component biogenesis at cellular level                 | 27       | 20.5         | 338        | 6.9        | 1.42E-02             |
|       | cytokinetic cell separation                                     | 8        | 6.1          | 31         | 0.6        | 1.71E-02             |
|       | cellular cell wall organization                                 | 11       | 8.3          | 75<br>75   | 1.5        | 2.23E-02             |
|       | ribonucleoprotein complex biogenesis                            | 27       | 20.5         | 259        | 5.3        | 2.46E-02             |
|       | external encapsulating structure organization                   | 11       | 8.3          | 76         | 1.5        | 2.46E-02             |
|       | fungal-type cell wall   | 8        | 6.1          | 36         | 0.7        | 4.78E-02             |
|       | cellular component biogenesis                                   | 27       | 20.5         | 610        | 12.4       | 5.24E-02             |
| alone | DNA integration   | 11       | 4.1          | 11         | 0.2        | 5.76E-08             |
| uont  | transposition   | 11       | 4.1          | 12         | 0.2        | 3.17E-07             |
|       | RNA-dependent DNA replication                                   | 11       | 4.1          | 15         | 0.3        | 6.03E-07             |
|       | RNA-directed DNA polymerase activity                            | 11       | 4.1          | 13         | 0.3        | 9.46E-07             |
|       | cen cycle<br>aspartic-type endopentidase activity               | 61<br>11 | 22.8<br>4 1  | 127        | 14.8       | 0.//E-06<br>2.34E-05 |
|       | aspartic-type endopeptidase activity                            | 11       | 4.1          | 16         | 0.3        | 2.34E-05             |
|       | UDP-glycosyltransferase activity                                | 6        | 2.2          | 27         | 0.5        | 2.96E-05             |
|       | cell cycle process  | 31       | 11.6         | 594        | 12.1       | 2.96E-05             |
|       | cell cycle phase  | 31       | 11.6         | 550        | 11.2       | 4.90E-05             |
|       | chromosome, centromenc region                                   | 19       | /.1<br>16.5  | 94<br>306  | 1.9        | 5.35E-05<br>8.87E-05 |
|       | microtubule cytoskeleton  | 33       | 12.4         | 176        | 3.6        | 1.11E-04             |
|       | transferase activity, transferring phosphorus-containing groups | 50       | 18.7         | 301        | 6.1        | 5.61E-04             |
|       | cell septum   | 44       | 16.5         | 239        | 4.9        | 5.61E-04             |
|       | DNA polymerase activity   | 11       | 4.1          | 30         | 0.6        | 6.70E-04             |
|       | Interphase<br>DNA hinding                                       | 5        | 1.9<br>21.7  | 60<br>361  | 1.2        | 6./0E-04<br>7.20E-04 |
|       | biological regulation   | 30<br>39 | 21.7<br>14.6 | 1299       | 26.4       | 1.18E-03             |
|       | mitotic cell cycle  | 31       | 11.6         | 259        | 5.3        | 1.73E-03             |
|       | kinetochore   | 12       | 4.5          | 65         | 1.3        | 1.95E-03             |
|       | signaling   | 24       | 9.0          | 383        | 7.8        | 1.95E-03             |
|       | cell wall organization or biogenesis                            | 25<br>54 | 9.4          | 122        | 2.5        | 1.95E-03             |
|       | cellular component organization or biogenesis at cellular level | 53       | 20.2<br>19.9 | 1420       | 29.0       | 2.12E-03<br>2.12E-03 |
|       | spindle   | 19       | 7.1          | 137        | 2.8        | 2.18E-03             |
|       | M phase   | 28       | 10.5         | 518        | 10.5       | 2.53E-03             |
|       | protein kinase activity   | 26       | 9.7          | 118        | 2.4        | 2.53E-03             |
|       | protein phosphorylation   | 28       | 10.5         | 125        | 2.5        | 2.53E-03             |

| regulation of call size  | 1  | 0.4  | 30  | 0.6  | 2.65E-03   |
|--|--|--|---|--|--|
| cellular cell wall organization or biogenesis  | 25   | 9.4  | 120   | 2.4  | 2.05E-03   |
| signal transduction  | 23   | 9.4  | 362   | 7.4  | 4.06E-03   |
| signaling process  | 24   | 9.0  | 363   | 7.4  | 4.00E 03   |
| signal transmission  | 24   | 9.0  | 363   | 7.4  | 4.21E-03   |
| regulation of nitrogen compound metabolic process  | 1  | 0.4  | 537   | 10.9   | 4.42E-03   |
| regulation of cellular process   | 36   | 13.5   | 1053  | 21.4   | 4.55E-03   |
| mitosis  | 28   | 10.5   | 182   | 3.7  | 4.97E-03   |
| regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process  | 1  | 0.4  | 531   | 10.8   | 4.97E-03   |
| chromosome   | 25   | 9.4  | 409   | 8.3  | 4.97E-03   |
| M phase of mitotic cell cycle  | 28   | 10.5   | 183   | 3.7  | 5.20E-03   |
| condensed chromosome, centromeric region   | 13   | 4.9  | 66  | 1.3  | 5.20E-03   |
| fungal-type cell wall organization or biogenesis   | 11   | 4.1  | 72  | 1.5  | 5.20E-03   |
| barrier septum   | 41   | 15.4   | 230   | 4.7  | 5.52E-03   |
| nuclear division   | 28   | 10.5   | 184   | 3.7  | 5.53E-03   |
| protein serine/threonine kinase activity   | 25   | 9.4  | 113   | 2.3  | 6.56E-03   |
| chromosomal part   | 19   | 7.1  | 391   | 8.0  | 7.88E-03   |
| cytoskeletal part  | 31   | 11.6   | 242   | 4.9  | 7.91E-03   |
| organelle fission  | 28   | 10.5   | 188   | 3.8  | 8.32E-03   |
| cytoskeleton   | 36   | 13.5   | 267   | 5.4  | 8.35E-03   |
| DNA replication  | 20   | 7.5  | 130   | 2.6  | 9.45E-03   |
| regulation of biological process   | 39   | 14.6   | 1134  | 23.1   | 9.91E-03   |
| phosphotransferase activity, alcohol group as acceptor   | 28   | 10.5   | 169   | 3.4  | 1.22E-02   |
| regulation of cellular metabolic process   | 1  | 0.4  | 661   | 13.5   | 1.40E-02   |
| fungal-type cell wall biogenesis   | 11   | 4.1  | 60  | 1.2  | 1.67E-02   |
| ATP binding  | 69   | 25.8   | 483   | 9.8  | 1.75E-02   |
| nucleotidyltransferase activity  | 18   | 6.7  | 93  | 1.9  | 1.80E-02   |
| adenyl ribonucleotide binding  | 69   | 25.8   | 485   | 9.9  | 1.94E-02   |
| interphase of mitotic cell cycle   | 5  | 1.9  | 55  | 1.1  | 2.01E-02   |
| cellular component organization  | 45   | 16.9   | 1196  | 24.3   | 2.36E-02   |
| cellular cell wall organization  | 15   | 5.6  | 75  | 1.5  | 2.39E-02   |
| cell wall organization   | 15   | 5.6  | 75  | 1.5  | 2.39E-02   |
| ATP-dependent helicase activity  | 15   | 5.6  | 76  | 1.5  | 2.76E-02   |
| external encapsulating structure organization  | 15   | 5.6  | 76  | 1.5  | 2.76E-02   |
| purine NTP-dependent helicase activity   | 15   | 5.6  | 76  | 1.5  | 2.76E-02   |
| transferase activity   | 76   | 28.5   | 659   | 13.4   | 2.98E-02   |
| cell wall biogenesis   | 12   | 4.5  | 70  | 1.4  | 2.98E-02   |
| nucleic acid binding   | 76   | 28.5   | 792   | 16.1   | 2.99E-02   |
| ATP-dependent DNA helicase activity  | 7  | 2.6  | 34  | 0.7  | 2.99E-02   |
| chromosome segregation   | 25   | 9.4  | 187   | 3.8  | 3.05E-02   |
| condensed chromosome   | 13   | 4.9  | 91  | 1.9  | 3.25E-02   |
| regulation of metabolic process  | 3  | 1.1  | 767   | 15.6   | 3.39E-02   |
| nucleoside binding   | 70   | 26.2   | 526   | 10.7   | 3.77E-02   |
| microtubule  | 15   | 5.6  | 59  | 1.2  | 3.86E-02   |
| transferase activity, transferring hexosyl groups  | 6  | 2.2  | 72  | 1.5  | 3.86E-02   |
| condensed chromosome kinetochore   | 8  | 3.0  | 60  | 1.2  | 4.62E-02   |
| DNA helicase activity  | 7  | 2.6  | 36  | 0.7  | 4.70E-02   |
| regulation of DNA-dependent DNA replication initiation   | 1  | 0.4  | 36  | 0.7  | 4.70E-02   |
| DNA-dependent ATPase activity  | 7  | 2.6  | 54  | 1.1  | 4.77E-02   |
| hydrolase activity, hydrolyzing O-glycosyl compounds   | 3  | 1.1  | 48  | 1.0  | 4.89E-02   |
| slm9 ∆   |  |  |   |  |  |
| ribosome biogenesis  | 40   | 48.2   | 235   | 4.8  | 7.37E-11   |
| cellular component biogenesis at cellular level  | 40   | 48.2   | 338   | 6.9  | 4.25E-10   |
| ribonucleoprotein complex biogenesis   | 40   | 48.2   | 259   | 5.3  | 9.56E-10   |
| ncRNA processing   | 29   | 34.9   | 246   | 5.0  | 2.30E-09   |
| rKNA processing  | 29   | 34.9   | 169   | 3.4  | 3.02E-09   |
| rKNA metabolic process   | 29   | 34.9   | 170   | 3.5  | 3.02E-09   |
| DNA (1)  | 40   | 48.2   | 610   | 12.4   | 2.73E-08   |
| ncKNA metabolic process  | 29   | 34.9   | 286   | 5.8  | 1.93E-07   |
| central component organization of biogenesis   | 42   | 12.5   | 220   | 29.0   | 1.5/E-00   |
| nucleoius  | 42   | 50.6   | 520   | 0.5  | 1.04E-00   |
| nuclear fumer  | 42   | 30.0   | 1246  | 27.4   | 3.30E-00   |
| cell division  | 20   | 3/ 0   | 306   | 67   | 3.49E-04   |
| RNA processing   |  | 54.7   | 441   | 9.0  | 2.12E-03   |
| in a processing  | 30   | 36.1   | 441   | 2.0  | 2.12L <sup>-</sup> 0J  |
| nuclear part   | 30<br>42   | 36.1<br>50.6   | 441<br>1084   | 22.1   | 3 41E-03   |
| nuclear part   | 30<br>42<br>42   | 36.1<br>50.6<br>50.6   | 441<br>1084<br>717  | 22.1<br>14.6   | 3.41E-03<br>2.04E-02   |
| nuclear part<br>organelle lumen<br>intracellular organelle lumen   | 30<br>42<br>42<br>42   | 36.1<br>50.6<br>50.6<br>50.6   | 441<br>1084<br>717<br>717   | 22.1<br>14.6<br>14.6   | 3.41E-03<br>2.04E-02<br>2.04E-02   |
| nuclear part<br>organelle lumen<br>intracellular organelle lumen<br>RNA metabolic process  | 30<br>42<br>42<br>42<br>30   | 36.1<br>50.6<br>50.6<br>50.6<br>36.1   | 441<br>1084<br>717<br>717<br>786  | 22.1<br>14.6<br>14.6<br>16.0   | 3.41E-03<br>2.04E-02<br>2.04E-02<br>2.30E-02   |
| nuclear part<br>organelle lumen<br>intracellular organelle lumen<br>RNA metabolic process<br>mitosis   | 30<br>42<br>42<br>42<br>30<br>20   | 36.1<br>50.6<br>50.6<br>50.6<br>36.1<br>24.1   | 441<br>1084<br>717<br>717<br>786<br>182   | 22.1<br>14.6<br>14.6<br>16.0<br>3.7  | 3.41E-03<br>2.04E-02<br>2.04E-02<br>2.30E-02<br>2.31E-02   |
| nuclear part<br>organelle lumen<br>intracellular organelle lumen<br>RNA metabolic process<br>mitosis<br>M phase of mitotic cell cycle  | 30<br>42<br>42<br>42<br>30<br>20<br>20   | 36.1<br>50.6<br>50.6<br>36.1<br>24.1<br>24.1   | 441<br>1084<br>717<br>717<br>786<br>182<br>183  | 22.1<br>14.6<br>14.6<br>16.0<br>3.7<br>3.7   | 3.41E-03<br>2.04E-02<br>2.04E-02<br>2.30E-02<br>2.31E-02<br>2.40E-02   |
| nuclear part<br>organelle lumen<br>intracellular organelle lumen<br>RNA metabolic process<br>mitosis<br>M phase of mitotic cell cycle<br>nuclear division  | 30<br>42<br>42<br>42<br>30<br>20<br>20<br>20   | 36.1<br>50.6<br>50.6<br>36.1<br>24.1<br>24.1<br>24.1   | 441<br>1084<br>717<br>717<br>786<br>182<br>183<br>184   | 22.1<br>14.6<br>16.0<br>3.7<br>3.7<br>3.7  | 3.41E-03<br>2.04E-02<br>2.04E-02<br>2.30E-02<br>2.31E-02<br>2.40E-02<br>2.50E-02   |
| nuclear part<br>organelle lumen<br>intracellular organelle lumen<br>RNA metabolic process<br>mitosis<br>M phase of mitotic cell cycle<br>nuclear division<br>cell septum   | 30<br>42<br>42<br>42<br>30<br>20<br>20<br>20<br>20<br>20<br>2  | 36.1<br>50.6<br>50.6<br>36.1<br>24.1<br>24.1<br>24.1<br>2.4  | 441<br>1084<br>717<br>717<br>786<br>182<br>183<br>184<br>239  | 22.1<br>14.6<br>14.6<br>16.0<br>3.7<br>3.7<br>3.7<br>4.9   | 3.41E-03<br>2.04E-02<br>2.04E-02<br>2.30E-02<br>2.31E-02<br>2.40E-02<br>2.50E-02<br>3.14E-02   |
| nuclear part<br>organelle lumen<br>intracellular organelle lumen<br>RNA metabolic process<br>mitosis<br>M phase of mitotic cell cycle<br>nuclear division<br>cell septum<br>organelle fission  | 30<br>42<br>42<br>42<br>30<br>20<br>20<br>20<br>20<br>20<br>20<br>20   | $36.1 \\ 50.6 \\ 50.6 \\ 36.1 \\ 24.1 \\ 24.1 \\ 24.1 \\ 2.4 \\ 2.4 \\ 24.1$   | 441<br>1084<br>717<br>717<br>786<br>182<br>183<br>184<br>239<br>188   | 22.1<br>14.6<br>14.6<br>16.0<br>3.7<br>3.7<br>3.7<br>4.9<br>3.8  | 3.41E-03<br>2.04E-02<br>2.04E-02<br>2.30E-02<br>2.31E-02<br>2.40E-02<br>2.50E-02<br>3.14E-02<br>3.21E-02   |
| nuclear part<br>organelle lumen<br>intracellular organelle lumen<br>RNA metabolic process<br>mitosis<br>M phase of mitotic cell cycle<br>nuclear division<br>cell septum<br>organelle fission<br>membrane-enclosed lumen   | 30<br>42<br>42<br>30<br>20<br>20<br>20<br>20<br>20<br>20<br>42   | $\begin{array}{c} 36.1 \\ 50.6 \\ 50.6 \\ 50.6 \\ 36.1 \\ 24.1 \\ 24.1 \\ 24.1 \\ 24.1 \\ 2.4 \\ 24.1 \\ 50.6 \\ \end{array}$  | 441<br>1084<br>717<br>786<br>182<br>183<br>184<br>239<br>188<br>740   | 22.1<br>14.6<br>14.6<br>16.0<br>3.7<br>3.7<br>3.7<br>4.9<br>3.8<br>15.1  | 3.41E-03<br>2.04E-02<br>2.04E-02<br>2.30E-02<br>2.31E-02<br>2.40E-02<br>2.50E-02<br>3.14E-02<br>3.21E-02<br>3.77E-02   |
| nuclear part<br>organelle lumen<br>intracellular organelle lumen<br>RNA metabolic process<br>mitosis<br>M phase of mitotic cell cycle<br>nuclear division<br>cell septum<br>organelle fission<br>membrane-enclosed lumen<br>hip1 A   | 30<br>42<br>42<br>30<br>20<br>20<br>20<br>2<br>20<br>2<br>20<br>42   | 36.1<br>50.6<br>50.6<br>36.1<br>24.1<br>24.1<br>24.1<br>24.1<br>2.4<br>24.1<br>50.6  | 441<br>1084<br>717<br>717<br>786<br>182<br>183<br>184<br>239<br>188<br>740  | 22.1<br>14.6<br>14.6<br>16.0<br>3.7<br>3.7<br>3.7<br>4.9<br>3.8<br>15.1  | 3.41E-03<br>2.04E-02<br>2.04E-02<br>2.30E-02<br>2.31E-02<br>2.40E-02<br>2.50E-02<br>3.14E-02<br>3.21E-02<br>3.77E-02   |
| nuclear part<br>organelle lumen<br>intracellular organelle lumen<br>RNA metabolic process<br>mitosis<br>M phase of mitotic cell cycle<br>nuclear division<br>cell septum<br>organelle fission<br>membrane-enclosed lumen<br><i>hip1</i> ∆<br>rRNA processing   | 30<br>42<br>42<br>42<br>20<br>20<br>20<br>20<br>2<br>20<br>42<br>21  | 36.1<br>50.6<br>50.6<br>36.1<br>24.1<br>24.1<br>24.1<br>24.1<br>2.4<br>24.1<br>50.6<br>40.4  | 441<br>1084<br>717<br>716<br>182<br>183<br>184<br>239<br>188<br>740<br>169  | 22.1<br>14.6<br>14.6<br>16.0<br>3.7<br>3.7<br>3.7<br>4.9<br>3.8<br>15.1<br>3.4   | 3.41E-03<br>2.04E-02<br>2.04E-02<br>2.30E-02<br>2.31E-02<br>2.40E-02<br>2.50E-02<br>3.14E-02<br>3.21E-02<br>3.77E-02<br>9.28E-05   |
| nuclear part<br>organelle lumen<br>intracellular organelle lumen<br>RNA metabolic process<br>mitosis<br>M phase of mitotic cell cycle<br>nuclear division<br>cell septum<br>organelle fission<br>membrane-enclosed lumen<br><i>hip1</i> Δ<br>rRNA processing<br>rRNA metabolic process   | 30<br>42<br>42<br>30<br>20<br>20<br>20<br>20<br>42<br>21<br>21   | 36.1<br>50.6<br>50.6<br>36.1<br>24.1<br>24.1<br>24.1<br>24.1<br>2.4<br>24.1<br>50.6<br>40.4<br>40.4  | 441<br>1084<br>717<br>786<br>182<br>183<br>184<br>239<br>188<br>740<br>169<br>170   | 22.1<br>14.6<br>14.6<br>16.0<br>3.7<br>3.7<br>3.7<br>4.9<br>3.8<br>15.1<br>3.4<br>3.5  | 3.41E-03<br>2.04E-02<br>2.30E-02<br>2.31E-02<br>2.40E-02<br>2.40E-02<br>2.50E-02<br>3.14E-02<br>3.21E-02<br>3.77E-02<br>9.28E-05<br>9.28E-05   |
| nuclear part<br>organelle lumen<br>intracellular organelle lumen<br>RNA metabolic process<br>mitosis<br>M phase of mitotic cell cycle<br>nuclear division<br>cell septum<br>organelle fission<br>membrane-enclosed lumen<br><i>hip1</i> <b>Δ</b><br>rRNA processing<br>rRNA processing<br>ncRNA processing   | 30<br>42<br>42<br>42<br>20<br>20<br>20<br>20<br>20<br>20<br>20<br>20<br>20<br>20<br>20<br>21<br>21<br>21   | 36.1<br>50.6<br>50.6<br>36.1<br>24.1<br>24.1<br>24.1<br>24.1<br>24.1<br>24.1<br>50.6<br>40.4<br>40.4<br>40.4   | 441<br>1084<br>717<br>717<br>786<br>182<br>183<br>184<br>239<br>188<br>740<br>169<br>170<br>246   | 22.1<br>14.6<br>16.0<br>3.7<br>3.7<br>3.7<br>4.9<br>3.8<br>15.1<br>3.4<br>3.5<br>5.0   | 3.41E-03<br>2.04E-02<br>2.30E-02<br>2.31E-02<br>2.40E-02<br>2.40E-02<br>2.50E-02<br>3.14E-02<br>3.21E-02<br>3.21E-02<br>3.77E-02<br>9.28E-05<br>9.28E-05<br>9.28E-05   |
| nuclear part<br>organelle lumen<br>intracellular organelle lumen<br>RNA metabolic process<br>mitosis<br>M phase of mitotic cell cycle<br>nuclear division<br>cell septum<br>organelle fission<br>membrane-enclosed lumen<br><i>hipt A</i><br>rRNA processing<br>rRNA metabolic process<br>ncRNA processing<br>ribosome biogenesis  | 30<br>42<br>42<br>42<br>30<br>20<br>20<br>20<br>20<br>20<br>20<br>20<br>20<br>20<br>20<br>21<br>21<br>21<br>21<br>27   | $36.1 \\ 50.6 \\ 50.6 \\ 50.6 \\ 36.1 \\ 24.1 \\ 24.1 \\ 24.1 \\ 24.1 \\ 24.1 \\ 50.6 \\ 40.4 \\ 40.4 \\ 40.4 \\ 51.9 \\ 51.9 \\ 50.6 \\ $ | 441<br>1084<br>717<br>717<br>786<br>182<br>183<br>184<br>239<br>188<br>740<br>169<br>170<br>246<br>235  | 22.1<br>14.6<br>14.6<br>16.0<br>3.7<br>3.7<br>3.7<br>4.9<br>3.8<br>15.1<br>3.4<br>3.5<br>5.0<br>4.8  | 3.41E-03<br>2.04E-02<br>2.04E-02<br>2.30E-02<br>2.31E-02<br>2.40E-02<br>2.50E-02<br>3.21E-02<br>3.21E-02<br>3.77E-02<br>9.28E-05<br>9.28E-05<br>9.28E-05   |
| nuclear part<br>organelle lumen<br>intracellular organelle lumen<br>RNA metabolic process<br>mitosis<br>M phase of mitotic cell cycle<br>nuclear division<br>cell septum<br>organelle fission<br>membrane-enclosed lumen<br><i>hip1 A</i><br>rRNA processing<br>rRNA metabolic process<br>ncRNA processing<br>ribosome biogenesis<br>cellular component biogenesis at cellular level   | 30<br>42<br>42<br>42<br>30<br>20<br>20<br>2<br>20<br>2<br>20<br>2<br>20<br>2<br>20   | $36.1 \\ 50.6 \\ 50.6 \\ 50.6 \\ 36.1 \\ 24.1 \\ 24.1 \\ 24.1 \\ 24.1 \\ 2.4 \\ 24.1 \\ 50.6 \\ 40.4 \\ 40.4 \\ 40.4 \\ 40.4 \\ 51.9 \\ 5$ | 441<br>1084<br>717<br>717<br>786<br>182<br>183<br>184<br>239<br>188<br>740<br>169<br>170<br>246<br>235<br>338   | 22.1<br>14.6<br>14.6<br>16.0<br>3.7<br>3.7<br>4.9<br>3.8<br>15.1<br>3.4<br>3.5<br>5.0<br>4.8<br>6.9  | 3.41E-03<br>2.04E-02<br>2.04E-02<br>2.31E-02<br>2.31E-02<br>2.40E-02<br>2.50E-02<br>3.14E-02<br>3.21E-02<br>3.77E-02<br>9.28E-05<br>9.28E-05<br>9.28E-05<br>9.28E-05   |
| nuclear part<br>organelle lumen<br>intracellular organelle lumen<br>RNA metabolic process<br>mitosis<br>M phase of mitotic cell cycle<br>nuclear division<br>cell septum<br>organelle fission<br>membrane-enclosed lumen<br><i>hip1</i> Δ<br>rRNA processing<br>rRNA metabolic process<br>ncRNA processing<br>ribosome biogenesis<br>cellular component biogenesis at cellular level<br>ribonucleoprotein complex biogenesis   | 30<br>42<br>42<br>42<br>20<br>20<br>20<br>22<br>20<br>42<br>21<br>21<br>21<br>21<br>21<br>21<br>27<br>27<br>27<br>27   | $36.1 \\ 50.6 \\ 50.6 \\ 50.6 \\ 36.1 \\ 24.1 \\ 24.1 \\ 24.1 \\ 24.1 \\ 2.4 \\ 24.1 \\ 50.6 \\ 40.4 \\ 40.4 \\ 40.4 \\ 40.4 \\ 51.9 \\ 5$ | 441<br>1084<br>717<br>717<br>786<br>182<br>183<br>184<br>239<br>188<br>740<br>169<br>170<br>246<br>235<br>338<br>259  | 22.1<br>14.6<br>16.0<br>3.7<br>3.7<br>4.9<br>3.8<br>15.1<br>3.4<br>3.5<br>5.0<br>4.8<br>6.9<br>5.3   | 3.41E-03<br>2.04E-02<br>2.04E-02<br>2.31E-02<br>2.40E-02<br>2.50E-02<br>3.14E-02<br>3.21E-02<br>3.77E-02<br>9.28E-05<br>9.28E-05<br>9.28E-05<br>9.28E-05<br>7.00E-04   |
| nuclear part<br>organelle lumen<br>intracellular organelle lumen<br>RNA metabolic process<br>mitosis<br>M phase of mitotic cell cycle<br>nuclear division<br>cell septum<br>organelle fission<br>membrane-enclosed lumen<br><i>hip1</i> Δ<br>rRNA processing<br>rRNA metabolic process<br>ncRNA processing<br>ribosome biogenesis at cellular level<br>ribonucleoprotein complex biogenesis<br>ncRNA metabolic process   | 30<br>42<br>42<br>42<br>20<br>20<br>20<br>20<br>20<br>20<br>20<br>20<br>20<br>20<br>21<br>21<br>21<br>21<br>27<br>27<br>21   | $\begin{array}{c} 36.1 \\ 50.6 \\ 50.6 \\ 50.6 \\ 36.1 \\ 24.1 \\ 24.1 \\ 24.1 \\ 24.1 \\ 24.1 \\ 24.1 \\ 50.6 \\ \hline \\ 40.4 \\ 40.4 \\ 40.4 \\ 51.9 \\ 51.9 \\ 51.9 \\ 51.9 \\ 40.4 \\ \end{array}$   | 441<br>1084<br>717<br>717<br>786<br>182<br>183<br>184<br>239<br>188<br>740<br>169<br>170<br>246<br>235<br>338<br>259<br>286   | $\begin{array}{c} 22.1\\ 14.6\\ 14.6\\ 16.0\\ 3.7\\ 3.7\\ 3.7\\ 4.9\\ 3.8\\ 15.1\\ \hline \\ 3.4\\ 3.5\\ 5.0\\ 4.8\\ 6.9\\ 5.3\\ 5.8\\ \end{array}$  | 3.41E-03<br>2.04E-02<br>2.30E-02<br>2.31E-02<br>2.40E-02<br>2.40E-02<br>2.50E-02<br>3.14E-02<br>3.21E-02<br>3.21E-02<br>3.77E-02<br>9.28E-05<br>9.28E-05<br>9.28E-05<br>9.28E-05<br>9.28E-05<br>9.28E-05<br>9.28E-05<br>9.28E-05<br>9.28E-05<br>9.28E-05<br>9.28E-05<br>9.28E-05   |
| nuclear part<br>organelle lumen<br>intracellular organelle lumen<br>RNA metabolic process<br>mitosis<br>M phase of mitotic cell cycle<br>nuclear division<br>cell septum<br>organelle fission<br>membrane-enclosed lumen<br><i>hip1 A</i><br>rRNA processing<br>rRNA metabolic process<br>ncRNA processing<br>ribosome biogenesis at cellular level<br>ribonucleoprotein complex biogenesis<br>cellular component biogenesis<br>ncRNA metabolic process<br>cellular component biogenesis   | 30<br>42<br>42<br>42<br>30<br>20<br>20<br>20<br>20<br>20<br>20<br>20<br>20<br>20<br>20<br>20<br>21<br>21<br>27<br>27<br>27<br>21<br>27<br>27   | $\begin{array}{c} 36.1 \\ 50.6 \\ 50.6 \\ 50.6 \\ 36.1 \\ 24.1 \\ 24.1 \\ 24.1 \\ 24.1 \\ 24.1 \\ 50.6 \\ \end{array}$ $\begin{array}{c} 40.4 \\ 40.4 \\ 40.4 \\ 40.4 \\ 51.9 \\ 51.9 \\ 51.9 \\ 51.9 \\ 40.4 \\ 51.9 \end{array}$   | 441<br>1084<br>717<br>717<br>786<br>182<br>183<br>184<br>239<br>188<br>740<br>169<br>170<br>246<br>235<br>338<br>259<br>286<br>610  | 22.1<br>14.6<br>16.0<br>3.7<br>3.7<br>3.7<br>4.9<br>3.8<br>15.1<br>3.4<br>3.5<br>5.0<br>4.8<br>6.9<br>5.3<br>5.8<br>12.4   | 3.41E-03<br>2.04E-02<br>2.30E-02<br>2.31E-02<br>2.40E-02<br>2.40E-02<br>2.50E-02<br>3.14E-02<br>3.21E-02<br>3.77E-02<br>9.28E-05<br>9.28E-05<br>9.28E-05<br>9.28E-05<br>9.28E-05<br>9.28E-05<br>9.28E-05<br>9.28E-05<br>9.28E-05<br>9.28E-05<br>7.00E-04<br>1.65E-03<br>7.76E-03   |
| nuclear part<br>organelle lumen<br>intracellular organelle lumen<br>RNA metabolic process<br>mitosis<br>M phase of mitotic cell cycle<br>nuclear division<br>cell septum<br>organelle fission<br>membrane-enclosed lumen<br><i>hip1 A</i><br>rRNA processing<br>rRNA processing<br>rRNA metabolic process<br>ncRNA processing<br>ribosome biogenesis<br>cellular component biogenesis at cellular level<br>ribonucleoprotein complex biogenesis<br>ncRNA metabolic process<br>cellular component biogenesis<br>cellular component biogenesis | 30<br>42<br>42<br>42<br>20<br>20<br>20<br>2<br>20<br>20<br>2<br>20<br>20<br>20<br>20<br>20<br>20<br>2  | $\begin{array}{c} 36.1 \\ 50.6 \\ 50.6 \\ 50.6 \\ 36.1 \\ 24.1 \\ 24.1 \\ 24.1 \\ 24.1 \\ 24.1 \\ 50.6 \\ \hline \\ 40.4 \\ 40.4 \\ 40.4 \\ 40.4 \\ 51.9 \\ 51.9 \\ 51.9 \\ 51.9 \\ 51.9 \\ 51.9 \\ 40.4 \\ 51.9 \\ 51.9 \\ 42.3 \\ \end{array}$   | 1084<br>717<br>717<br>786<br>182<br>183<br>184<br>239<br>188<br>740<br>169<br>170<br>246<br>235<br>338<br>259<br>286<br>610<br>306  | $\begin{array}{c} 22.1\\ 14.6\\ 14.6\\ 16.0\\ 3.7\\ 3.7\\ 3.7\\ 4.9\\ 3.8\\ 15.1\\ \hline \\ 3.4\\ 3.5\\ 5.0\\ 4.8\\ 6.9\\ 5.3\\ 5.8\\ 12.4\\ 6.2\\ \end{array}$   | 3.41E-03<br>2.04E-02<br>2.04E-02<br>2.31E-02<br>2.31E-02<br>2.40E-02<br>2.50E-02<br>3.14E-02<br>3.21E-02<br>3.77E-02<br>9.28E-05<br>9.28E-05<br>9.28E-05<br>9.28E-05<br>9.28E-05<br>9.28E-05<br>9.28E-05<br>7.00E-04<br>1.65E-03<br>1.56E-02   |
| nuclear part<br>organelle lumen<br>intracellular organelle lumen<br>RNA metabolic process<br>mitosis<br>M phase of mitotic cell cycle<br>nuclear division<br>cell septum<br>organelle fission<br>membrane-enclosed lumen<br><i>hip1</i> Δ<br>rRNA processing<br>rRNA metabolic process<br>ncRNA processing<br>ribosome biogenesis<br>cellular component biogenesis at cellular level<br>ribonucleoprotein complex biogenesis<br>ncRNA metabolic process<br>cellular component biogenesis<br>cellular component biogenesis<br>cellular component biogenesis   | 30<br>42<br>42<br>42<br>30<br>20<br>20<br>2<br>20<br>20<br>22<br>20<br>42<br>21<br>21<br>21<br>21<br>21<br>27<br>27<br>27<br>27<br>21<br>27<br>27<br>22<br>4   | 36.1 $50.6$ $50.6$ $36.1$ $24.1$ $24.1$ $24.1$ $2.4$ $24.1$ $50.6$ $40.4$ $40.4$ $40.4$ $40.4$ $40.4$ $51.9$ $51.9$ $51.9$ $51.9$ $51.9$ $51.9$ $51.9$ $51.9$ $51.9$ $51.9$ $51.9$ $51.9$ $51.9$ $51.9$ $51.9$ $51.9$ $51.9$ $51.7$ $51.9$ $51.9$ $51.7$ $51.9$ $51.9$ $51.9$ $51.7$ $51.9$ $51.7$ $51.9$ $51.9$ $51.7$ $51.9$ $51.7$ $51.9$ $51.7$ $51.9$ $51.7$ $51.9$ $51.7$ $51.9$ $51.7$ $51.9$ $51.7$ $51.9$ $51.9$ $51.9$ $51.7$ $51.9$ $5$   | 441<br>1084<br>717<br>717<br>786<br>182<br>183<br>184<br>239<br>188<br>740<br>169<br>170<br>246<br>235<br>338<br>259<br>286<br>610<br>306<br>58                           | $\begin{array}{c} 22.1\\ 14.6\\ 14.6\\ 16.0\\ 3.7\\ 3.7\\ 3.7\\ 4.9\\ 3.8\\ 15.1\\ \hline \\ 3.4\\ 3.5\\ 5.0\\ 4.8\\ 6.9\\ 5.3\\ 5.8\\ 12.4\\ 6.2\\ 1.2\\ \end{array}$                                   | 3.41E-03<br>2.04E-02<br>2.30E-02<br>2.31E-02<br>2.40E-02<br>2.50E-02<br>3.14E-02<br>3.21E-02<br>3.77E-02<br>9.28E-05<br>9.28E-05<br>9.28E-05<br>9.28E-05<br>9.28E-05<br>7.00E-04<br>1.65E-03<br>7.76E-03<br>1.56E-02<br>2.50E-02   |
| nuclear part<br>organelle lumen<br>intracellular organelle lumen<br>RNA metabolic process<br>mitosis<br>M phase of mitotic cell cycle<br>nuclear division<br>cell septum<br>organelle fission<br>membrane-enclosed lumen<br><i>hip1</i> <b>Δ</b><br><i>r</i> RNA processing<br>rRNA processing<br>rRNA metabolic process<br>ncRNA processing<br>ribosome biogenesis at cellular level<br>ribonucleoprotein complex biogenesis<br>cellular component biogenesis<br>ncRNA metabolic process<br>cellular component biogenesis<br>cellular component biogenesis<br>cellular and the process<br>cellular component biogenesis<br>cellular component biogenesis<br>cellular and the process<br>cellular component biogenesis   | 30<br>42<br>42<br>42<br>30<br>20<br>20<br>2<br>20<br>20<br>2<br>20<br>42<br>21<br>21<br>21<br>21<br>21<br>27<br>27<br>21<br>27<br>21<br>27<br>21<br>27<br>21<br>27<br>24<br>4<br>4   | $\begin{array}{c} 36.1 \\ 50.6 \\ 50.6 \\ 50.6 \\ 36.1 \\ 24.1 \\ 24.1 \\ 24.1 \\ 24.1 \\ 24.1 \\ 50.6 \\ \hline \\ 40.4 \\ 40.4 \\ 40.4 \\ 40.4 \\ 51.9 \\ 51.9 \\ 51.9 \\ 51.9 \\ 40.4 \\ 51.9 \\ 51.9 \\ 40.4 \\ 51.9 \\ 51.9 \\ 40.4 \\ 51.9 \\ 7.7 \\ 7.7 \\ 7.7 \\ 7.7 \end{array}$  | 441<br>1084<br>717<br>717<br>786<br>182<br>183<br>184<br>239<br>188<br>740<br>169<br>170<br>246<br>235<br>338<br>259<br>286<br>610<br>306<br>58<br>58                     | $\begin{array}{c} 22.1 \\ 14.6 \\ 16.0 \\ 3.7 \\ 3.7 \\ 3.7 \\ 4.9 \\ 3.8 \\ 15.1 \\ \hline \end{array}$   | 3.41E-03<br>2.04E-02<br>2.30E-02<br>2.31E-02<br>2.40E-02<br>2.40E-02<br>2.40E-02<br>3.14E-02<br>3.21E-02<br>3.21E-02<br>3.77E-02<br>9.28E-05<br>9.28E-05<br>9.28E-05<br>9.28E-05<br>9.28E-05<br>9.28E-05<br>9.28E-05<br>7.00E-04<br>1.65E-03<br>7.76E-03<br>1.56E-02<br>2.50E-02   |
| nuclear part<br>organelle lumen<br>intracellular organelle lumen<br>RNA metabolic process<br>mitosis<br>M phase of mitotic cell cycle<br>nuclear division<br>cell septum<br>organelle fission<br>membrane-enclosed lumen<br><i>hip1 A</i><br>rRNA processing<br>rRNA processing<br>rRNA metabolic process<br>ncRNA processing<br>ribosome biogenesis at cellular level<br>ribonucleoprotein complex biogenesis<br>cellular component biogenesis<br>cellular component biogenesis<br>cellular component biogenesis<br>cellular and biogenesis<br>cellular component biogenesis<br>cellular component biogenesis<br>cellular component biogenesis<br>cell division<br>cell wall<br>external encapsulating structure<br>cellular component organization or biogenesis   | 30<br>42<br>42<br>42<br>30<br>20<br>20<br>20<br>20<br>20<br>20<br>20<br>20<br>20<br>20<br>21<br>21<br>21<br>21<br>27<br>27<br>21<br>27<br>27<br>21<br>27<br>27<br>21<br>27<br>27<br>21<br>27<br>27<br>21<br>27<br>27<br>27<br>27<br>27<br>27<br>27<br>27<br>27<br>27<br>27<br>27<br>27 | $\begin{array}{c} 36.1 \\ 50.6 \\ 50.6 \\ 50.6 \\ 36.1 \\ 24.1 \\ 24.1 \\ 24.1 \\ 24.1 \\ 24.1 \\ 50.6 \\ \hline \\ 40.4 \\ 40.4 \\ 40.4 \\ 40.4 \\ 51.9 \\ 51.9 \\ 51.9 \\ 51.9 \\ 51.9 \\ 51.9 \\ 40.4 \\ 51.9 \\ 51.9 \\ 42.3 \\ 7.7 \\ 7.7 \\ 51.9 \\ \hline \\ \end{array}$   | 441<br>1084<br>717<br>717<br>786<br>182<br>183<br>184<br>239<br>188<br>740<br>169<br>170<br>246<br>235<br>338<br>259<br>286<br>610<br>306<br>58<br>58<br>58<br>58<br>1426 | $\begin{array}{c} 22.1 \\ 14.6 \\ 16.0 \\ 3.7 \\ 3.7 \\ 3.7 \\ 3.7 \\ 3.8 \\ 15.1 \\ \hline \\ 3.4 \\ 3.5 \\ 5.0 \\ 4.8 \\ 6.9 \\ 5.3 \\ 5.8 \\ 12.4 \\ 6.2 \\ 1.2 \\ 1.2 \\ 29.0 \\ \hline \end{array}$ | 3.41E-03<br>2.04E-02<br>2.04E-02<br>2.30E-02<br>2.31E-02<br>2.40E-02<br>2.50E-02<br>3.14E-02<br>3.21E-02<br>3.77E-02<br>9.28E-05<br>9.28E-05<br>9.28E-05<br>9.28E-05<br>9.28E-05<br>9.28E-05<br>9.28E-05<br>9.28E-05<br>9.28E-05<br>9.28E-05<br>9.28E-05<br>9.28E-03<br>1.56E-03<br>1.56E-02<br>2.50E-02<br>2.50E-02<br>4.80E-02 |

#### SUPPLEMENTAL EXPERIMENTAL PROCEDURES

#### Chromatin fractionation assay

The chromatin fractionation assay was performed as described previously (S1,S2) with some modifications. Cells ( $5 \times 10^8$  cells) were harvested, suspended in ice-cold STOP buffer (150 mM NaCl, 50 mM NaF, 10 mM EDTA, 1 mM NaN<sub>3</sub>), and placed on ice for 5 min. The cell suspension was spun at 800 g for 1 min at 4°C, and the resulting cell pellet was resuspended in PEMS (100 mM PIPES [pH 6.9], 1 mM EGTA, 1 mM MgSO<sub>4</sub>, 1 M sorbitol) containing 1 mg/ml Lysing enzymes (Sigma) and 1 mg/ml Zymolyase 100T (Seikagaku Corporation). The suspension was incubated at 37°C until almost all the cells were spheroplasted (60-90 min). The cell suspension was spun at 2,300 g for 1 min at  $4^{\circ}$ C, and the resulting cell pellet was washed three times with ice-cold wash buffer (1 M sorbitol, 25 mM MOPS [pH 7.2]). Then, the cells were resuspended in HBS buffer (25 mM MOPS [pH 7.2], 15 mM MgCl<sub>2</sub>, 15 mM EGTA, 0.4 M sorbitol) containing 1 mM PMSF, 1×Complete (Roche), and 1% Triton X-100, and placed on ice for 5 min. The resulting whole-cell extract was spun at 20,400 g for 15 min at 4°C to obtain the supernatant (soluble fraction) and the pellet. The pellet was washed three times and resuspended in ice-cold digestion buffer (25 mM MOPS [pH 7.2], 15 mM MgCl<sub>2</sub>, 2.5 mM CaCl<sub>2</sub>, 0.4 M sorbitol) containing 1×Complete (Roche), and the suspension was incubated with 1 U/µl MNase for 2 min at 37°C. After centrifugation at 20,400 g for 5 min at 4°C, the pellet was digested once more with MNase as described above and the supernatants were combined (MNase fraction). The pellet was washed once with ice-cold digestion buffer and resuspended in ice-cold extraction buffer (25 mM MOPS [pH 7.2], 10 mM EDTA, 0.4 M sorbitol) containing  $1 \times$ Complete (Roche), and placed on ice for 5 min. Then, the suspension was spun at 20,400 g for 15 min at 4°C to obtain the supernatant (chromatin fraction) and the pellet. The pellet was washed two times with extraction buffer (pellet fraction). Proteins from each fraction were separated by SDS-PAGE and detected by Western blotting.

#### SUPPLEMENTAL REFERENCES

- S1. Ogawa, Y., Takahashi, T., and Masukata, H. (1999) *Mol Cell Biol* 19, 7228-7236
- S2. Sadaie, M., Kawaguchi, R., Ohtani, Y., Arisaka, F., Tanaka, K., Shirahige, K., and Nakayama, J. (2008) *Mol Cell Biol* **28**, 6973-6988